<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Innovations &#8211; Naturenal</title>
	<atom:link href="https://naturenal.com/category/innovations/feed/" rel="self" type="application/rss+xml" />
	<link>https://naturenal.com</link>
	<description>Kidney wellness resources</description>
	<lastBuildDate>Fri, 30 Oct 2026 01:12:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.4</generator>

<image>
	<url>https://naturenal.com/wp-content/uploads/2025/06/cropped-NatuRenal_logo-1-32x32.png</url>
	<title>Innovations &#8211; Naturenal</title>
	<link>https://naturenal.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Groundbreaking Pig Kidney Transplants: A Breakthrough Path to Mainstream Renal Xenografts</title>
		<link>https://naturenal.com/pig-kidney-transplant/</link>
					<comments>https://naturenal.com/pig-kidney-transplant/#respond</comments>
		
		<dc:creator><![CDATA[admin]]></dc:creator>
		<pubDate>Fri, 17 Oct 2025 21:23:14 +0000</pubDate>
				<category><![CDATA[Transplant]]></category>
		<category><![CDATA[Dialysis]]></category>
		<category><![CDATA[Innovations]]></category>
		<category><![CDATA[CKD innovations]]></category>
		<category><![CDATA[organ shortage solutions]]></category>
		<category><![CDATA[pig kidney transplant]]></category>
		<category><![CDATA[renal xenograft]]></category>
		<category><![CDATA[xenotransplant ethics]]></category>
		<guid isPermaLink="false">https://naturenal.com/?p=1342</guid>

					<description><![CDATA[Pig kidney transplant research has leapt from lab to clinic. Discover how CRISPR-edited porcine kidneys could revolutionize organ supply, what hurdles remain, and when renal xenografts might become routine care.]]></description>
										<content:encoded><![CDATA[
<h2 class="wp-block-heading">The Promise of Pig Kidney Transplants.</h2>



<p class="wp-block-paragraph">More than <strong>100 000</strong> Americans sit on the kidney-transplant wait-list today. A new option for transplantation is gaining traction.  Pig transplant kidneys are a resurgent hot-topic and with all of the recent headlines, an evidence-based update is needed to separate fact from fiction.  There is dire need for treatment options as the queue of patient&#8217;s seeking transplant grows by roughly a patient an hour. <a href="https://www.kidney.org/news-stories/clinical-trials-pig-to-human-kidney-transplantation-are-here" target="_blank" rel="noreferrer noopener">National Kidney Foundation</a> Dialysis buys time, but cardiovascular risk, hospital days, and quality-of-life penalties remain harsh. A single viable alternative could change everything: <strong>the pig kidney transplant</strong>. What sounded like science fiction a decade ago is edging toward clinical reality as CRISPR-engineered porcine organs clear ever-higher safety and efficacy bars for human xenografts.</p>



<p class="wp-block-paragraph">For patients and payers alike, the upside is enormous. A successful <strong>pig kidney transplant</strong> could:</p>



<ul class="wp-block-list">
<li>deliver immediate glomerular filtration without the ischemia time typical of deceased-donor grafts;</li>



<li>slash dialysis expenditures (~US $90 000 per patient-year) and uninsured emergency visits;</li>



<li>relieve the crushing psychosocial toll of indefinite “machine-life.”</li>
</ul>



<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p class="wp-block-paragraph"><strong>Internal link</strong>: For background on the growing CKD burden, see our <a href="/chronic-kidney-disease-rise">National Geographic wake-up call article</a>.</p>
</blockquote>



<hr class="wp-block-separator has-alpha-channel-opacity"/>



<h2 class="wp-block-heading">How Renal Xenografts Work</h2>



<ol class="wp-block-list">
<li><strong>Biosecure donor herds</strong>.  Pigs are reared in designated-pathogen-free (DPF) facilities, screened to eliminate porcine endogenous retroviruses (PERVs).</li>



<li><strong>CRISPR gene editing</strong>. Deletion of the α-Gal epitope and up-to-10 human “knock-ins” (e.g., CD46, thrombomodulin) blunt hyper-acute rejection and coagulation.</li>



<li><strong>Normothermic perfusion</strong> — Before implantation, the organ is flushed with oxygenated, hemoglobin-based solution to wash out residual porcine blood and prime endothelial metabolism.</li>



<li><strong>The operation</strong>. During the <strong>pig kidney transplant</strong>, surgeons anastomose the graft’s vessels and ureter to human counterparts; total clamp time now rivals routine living-donor surgery.</li>



<li><strong>Post-op management</strong>. Antibody-depleting induction plus costimulation-blockade (belatacept or anti-CD40) replaces calcineurin-heavy regimens, mitigating nephrotoxicity while targeting xenogeneic epitopes. KDIGO’s latest draft xenotransplant addendum echoes this approach.</li>
</ol>


<div class="wp-block-image">
<figure class="aligncenter size-full is-resized"><img fetchpriority="high" decoding="async" width="400" height="400" src="https://naturenal.com/wp-content/uploads/2025/10/transplant-OR.webp" alt="Surgical team implants a gene-edited pig kidney into a human recipient under bright OR lights." class="wp-image-1346" style="width:344px;height:auto" srcset="https://naturenal.com/wp-content/uploads/2025/10/transplant-OR.webp 400w, https://naturenal.com/wp-content/uploads/2025/10/transplant-OR-300x300.webp 300w, https://naturenal.com/wp-content/uploads/2025/10/transplant-OR-150x150.webp 150w, https://naturenal.com/wp-content/uploads/2025/10/transplant-OR-100x100.webp 100w" sizes="(max-width: 400px) 100vw, 400px" /></figure>
</div>


<hr class="wp-block-separator has-alpha-channel-opacity"/>



<h2 class="wp-block-heading">Recent Breakthroughs &amp; First-in-Human Trials</h2>



<div class="wp-block-group is-nowrap is-layout-flex wp-container-core-group-is-layout-8f761849 wp-block-group-is-layout-flex">
<ul class="wp-block-list">
<li><strong>32-day sentinel model (NYU Langone, 2023)</strong>. A gene-edited pig kidney transplant attached to a brain-dead donor produced urine and maintained creatinine for over a month, the longest functional xenograft on record at the time. <a href="https://nyulangone.org/news/pig-kidney-xenotransplantation-performing-optimally-after-32-days-human-body" target="_blank" rel="noreferrer noopener">NYU Langone Health</a></li>



<li><strong>First living recipient (Massachusetts General Hospital, March 2024)</strong>. 62-year-old Rick Slayman left dialysis days after surgery; the graft functioned until his unrelated death eight weeks later, proving surgical and short-term safety. <a href="https://www.massgeneral.org/news/press-release/worlds-first-genetically-edited-pig-kidney-transplant-into-living-recipient" target="_blank" rel="noreferrer noopener">Massachusetts General Hospital (1)</a></li>



<li><strong>130-day survival (NYU Langone, Nov 2024 – Apr 2025)</strong>. Alabama patient Towana Looney showed stable eGFR before immune escape forced graft removal at day 130, yielding critical data on antibody-mediated rejection kinetics and informing trial immunosuppression design. <a href="https://apnews.com/article/9fae82b85c98bf67398d5b4798977c2b" target="_blank" rel="noreferrer noopener">AP News</a></li>



<li><strong>Regulatory green light (FDA, Feb 2025)</strong>. Two biotech firms received IND approval to launch phase I “compassionate allotment” studies of <strong>pig kidney transplant</strong> candidates with high allo-sensitization scores. <a href="https://www.kidneyfund.org/article/fda-greenlights-first-clinical-trials-genetically-modified-pig-kidney-transplants-humans" target="_blank" rel="noreferrer noopener">American Kidney Fund</a></li>



<li><strong>Full clinical trials (NKF update, Aug 2025)</strong>. Nationwide enrollment began for prospective, single-arm studies targeting 60 participants across six centers, with 12-month graft-survival as the primary endpoint. <a href="https://www.kidney.org/news-stories/clinical-trials-pig-to-human-kidney-transplantation-are-here?utm_source=chatgpt.com" target="_blank" rel="noreferrer noopener">National Kidney Foundation</a></li>
</ul>
</div>



<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p class="wp-block-paragraph"><strong>Internal link</strong>: Curious how xenografts could offset dialysis economics? Our deep-dive on <a href="/dialysis-cost-drivers">dialysis cost drivers</a> breaks it down.</p>
</blockquote>



<h2 class="wp-block-heading">Safety, Ethics, and Public Perception</h2>



<p class="wp-block-paragraph">Imagine the surgical lights fading as Mr Slayman was wheeled from the OR &#8211; family hopeful, surgeons exhilarated, ethicists already arguing on X (PKA Twitter). This scene captures the polarity of the <strong>pig kidney transplant</strong> conversation. On one side, the promise of a readily-available organ; on the other, visceral unease about crossing a species line.</p>



<p class="wp-block-paragraph">A 2025 U.S. patient-attitude survey found barely <strong>13 %</strong> of respondents willing to enroll in a first-in-human xenograft trial. <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11800742/" target="_blank" rel="noreferrer noopener">PMC</a> A parallel UK poll echoed the ambivalence: acceptance rises once safety data accumulate, but two-thirds still voice concern about animal welfare and zoonotic risk. <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2825%2901195-X/fulltext" target="_blank" rel="noreferrer noopener">The Lancet</a> These worries cannot be summarily dismissed in the modern age, even when human lives are in the balance. Designer pigs live in <strong>$75 million biosecure barns</strong>, their air showered and their feed irradiated to keep PERV-free status. <a href="https://apnews.com/article/pig-organ-transplant-xenotransplant-revivicor-ad400e7f1d30c2722456eb92e641449f" target="_blank" rel="noreferrer noopener">AP News</a> </p>



<p class="wp-block-paragraph">Critics argue that “pathogen-free” can drift into “empathy-free” if regulatory inspections slacken. Religious scholars debate whether porcine DNA inside a human violates kosher or halal law; transplant chaplains counter with lived stories of dialysis demise. The ethics remain debatable, but the rising death toll from organ shortage keeps the main issues brutally grounded.</p>



<hr class="wp-block-separator has-alpha-channel-opacity"/>



<h2 class="wp-block-heading">Regulatory &amp; Supply-Chain Hurdles</h2>



<p class="wp-block-paragraph">In late-September 2025 the FDA released an updated <strong>Cellular &amp; Gene Therapy Guidance Agenda</strong> that, for the first time, lists xenotransplantation as a specific high-priority workstream. <a href="https://www.fda.gov/vaccines-blood-biologics/biologics-guidances/cellular-gene-therapy-guidances" target="_blank" rel="noreferrer noopener">U.S. Food and Drug Administration</a> Sponsors must demonstrate:</p>



<ol class="wp-block-list">
<li><strong>Source-animal traceability</strong> from embryo to operating room;</li>



<li><strong>Real-time PERV monitoring</strong> with release-criteria algorithms;</li>



<li><strong>Red-flag registries</strong> for recipients and close contacts extending 30 years.</li>
</ol>



<p class="wp-block-paragraph">Those requirements drive cost. Revivicor’s pathogen-free farm now logs each pig’s microbiome profile &#8211; an SOP that adds roughly <strong>US $15 000</strong> to every future <strong>pig kidney transplant</strong> before the organ leaves the gate. Scaling that to 25 000 grafts a year (today’s U.S. wait-list turnover) means an upstream supply chain comparable in budget to a mid-sized vaccine rollout. Add perfusion devices, CRISPR licensing fees, and xenograft-specific immunosuppressants and the launch price could rival CAR-T therapy.</p>



<p class="wp-block-paragraph">Logistics bite too: a kidney procured in Virginia must hit a New York OR within six hours, even with normothermic perfusion. That forces hubs near DPF farms, charter flights on demand, and transplant centers willing to re-engineer call schedules. Until payers see long-term actuarial savings, most programs will move cautiously before authorizing payment for human recipients of pig transplant kidneys.</p>



<hr class="wp-block-separator has-alpha-channel-opacity"/>



<h2 class="wp-block-heading">Clinical Impact for CKD Patients</h2>



<p class="wp-block-paragraph">Still, the human calculus is stark. Medicare projects <strong>US $273.82</strong> per hemodialysis session in 2025, or roughly <strong>US $90 000</strong> per beneficiary each year—not counting hospitalizations. <a href="https://www.cms.gov/newsroom/fact-sheets/calendar-year-2025-end-stage-renal-disease-esrd-prospective-payment-system-pps-final-rule-cms-1805-f" target="_blank" rel="noreferrer noopener">Centers for Medicare &amp; Medicaid Services</a> With rates slated to climb to <strong>US $281</strong> in 2026, <a href="https://www.cms.gov/newsroom/fact-sheets/calendar-year-cy-2026-end-stage-renal-disease-esrd-prospective-payment-system-proposed-rule-cms-1830" target="_blank" rel="noreferrer noopener">Centers for Medicare &amp; Medicaid Services (1)</a> every durable xenograft that frees a patient from the machine pays for itself within three to five years, even at a headline price north of US $300 000.</p>



<p class="wp-block-paragraph">Early compassionate-use data hint at more than cost offsets. Recipients describe “waking up without the dialysis fog,” normalizing phosphorus within days, and planning road trips impossible under thrice-weekly chair time. But access could mirror existing transplant disparities: rural and minority patients already face longer wait-times and fewer referrals; xenograft rollouts risk deepening that divide if high-volume centers charge concierge-style fees.</p>



<p class="wp-block-paragraph">For now, nephrologists should prep patients with level-headed counseling: a <strong>pig kidney transplant</strong> is not yet a ticket off the wait-list, but it is no longer science fiction. Encourage potential candidates, especially those with high PRA or multiple failed grafts, to follow trial openings and consider registry enrollment.</p>



<h2 class="wp-block-heading">Timeline to Mainstream Adoption</h2>



<p class="wp-block-paragraph"><strong>2025 – 2027 · “Pioneer Phase.”</strong><br>With Mr Rick Slayman’s historic <strong>pig kidney transplant</strong> at Massachusetts General Hospital (MGH) and Towana Looney’s 130-day run at NYU, the field crossed the safety threshold from brain-dead models to conscious recipients. <a href="https://www.massgeneral.org/news/press-release/worlds-first-genetically-edited-pig-kidney-transplant-into-living-recipient" target="_blank" rel="noreferrer noopener">Massachusetts General Hospital(2)</a> FDA reviewers responded by adding xenotransplantation to their high-priority agenda and re-issuing guidance that formalized pathogen-free sourcing and 30-year recipient surveillance. <a href="https://www.fda.gov/vaccines-blood-biologics/biologics-guidances/xenotransplantation-guidances" target="_blank" rel="noreferrer noopener">U.S. Food and Drug Administration</a> Over the next 24 months, phase-I “compassionate allotment” trials (≈60 patients) will probe thrombosis, delayed rejection, and immunosuppression load-balancing.</p>



<p class="wp-block-paragraph"><strong>2028 – 2030 · “Scaling Phase.”</strong><br>If one-year graft-survival tops <strong>70 %</strong> roughly par with marginal deceased-donor kidneys, CMS has signaled a willingness to bundle the procedure under the ESRD Prospective Payment System (PPS). The math is straightforward: the 2025 base dialysis rate is <strong>$273.82</strong> per session and projected to rise to <strong>$281.06</strong> in 2026. <a href="https://www.cms.gov/files/document/r13245bp.pdf" target="_blank" rel="noreferrer noopener">Centers for Medicare &amp; Medicaid Services(2)</a> A durable xenograft that liberates a patient from thrice-weekly chair time pays back its upfront cost within five years, even at CAR-T-level launch pricing. Hospitals that already run paired-kidney exchange algorithms could expand to include xenograft slots, smoothing OR schedules and lowering organ-logistics overhead.</p>



<p class="wp-block-paragraph"><strong>2031 – 2035 · “Mainstream Phase.”</strong><br>By the early 2030s, analysts expect supply-chain kinks with biosecure herds, charter flights, perfusion pumps to stabilize. Modeling studies presented at ASN Kidney Week 2025 predict that once annual production tops <strong>25 000</strong> grafts, unit cost drops below living-donor procurement. At that inflection point, most large U.S. centers will adopt <strong>pig kidney transplant</strong> programs; smaller hospitals will refer. Public sentiment is already inching forward: a 2025 UK/US survey found that acceptance climbs from 13 % to nearly 50 % once safety data exceed six months. <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2825%2901195-X/fulltext" target="_blank" rel="noreferrer noopener">The Lancet</a> If rejection-free survival pushes past two years, actuarial tables suggest insurers will green-light routine coverage.</p>



<hr class="wp-block-separator has-alpha-channel-opacity"/>



<h2 class="wp-block-heading">Take-Home Points &amp; Next Steps</h2>



<ol class="wp-block-list">
<li><strong>Not science fiction anymore.</strong> Three first-in-human successes prove surgical feasibility and short-term function.</li>



<li><strong>Regulation is catching up.</strong> FDA’s 2025 guidance lays a clear IND path; expect multi-center phase-II trials by late 2026.</li>



<li><strong>Economics favor adoption.</strong> Escalating dialysis PPS rates make a successful <strong>pig kidney transplant</strong> cost-effective within half a decade.</li>



<li><strong>Equity must stay front-of-mind.</strong> Rural and minority CKD patients already trail in referral rates; providers should track xenograft trial openings and advocate early.</li>



<li><strong>Stay informed.</strong> Follow works cited links as this article is evidence based.  Join naturenal.com e-mail subscriber list and return back to this page for updates.</li>
</ol>



<hr class="wp-block-separator has-alpha-channel-opacity"/>



<h3 class="wp-block-heading">Works Cited</h3>



<ol class="wp-block-list">
<li>Donate Life America. <strong>National Donate Life Month 2025: Donation &amp; Transplantation Statistics</strong>. 2025. <a href="https://donatelife.net/wp-content/uploads/2025-NDLM-Donation-and-Transplantation-Statistics.pdf" target="_blank" rel="noreferrer noopener">Donate Life America</a></li>



<li>Mass General Hospital. <em>World’s First Genetically-Edited Pig Kidney Transplant into Living Recipient</em>. Press release, Mar 21 2024.<a href="https://www.massgeneral.org/news/press-release/worlds-first-genetically-edited-pig-kidney-transplant-into-living-recipient" target="_blank" rel="noreferrer noopener">Massachusetts General Hospital</a></li>



<li>NYU Langone Health. <em>Pig Kidney Recipient Returns Home After Transplant Breakthrough</em>. Feb 25 2025.<a href="https://nyulangone.org/news/pig-kidney-recipient-returns-home-after-transplant-breakthrough-nyu-langone-health?utm_source=chatgpt.com" target="_blank" rel="noreferrer noopener">NYU Langone Health</a></li>



<li>Science. <em>Longest human transplant of pig kidney fails</em>. Apr 11 2025.<a href="https://www.science.org/content/article/longest-human-transplant-pig-kidney-fails" target="_blank" rel="noreferrer noopener">Science</a></li>



<li>FDA. <strong>Xenotransplantation Guidances</strong>. Updated Jun 17 2025.<a href="https://www.fda.gov/vaccines-blood-biologics/biologics-guidances/xenotransplantation-guidances" target="_blank" rel="noreferrer noopener">U.S. Food and Drug Administration</a></li>



<li>CMS. <strong>CY 2025 ESRD PPS Base Rate</strong>. May 29 2025.<a href="https://www.cms.gov/files/document/r13245bp.pdf" target="_blank" rel="noreferrer noopener">Centers for Medicare &amp; Medicaid Services</a></li>



<li>CMS. <strong>CY 2026 ESRD PPS Proposed Rule</strong>. Jun 30 2025.<a href="https://www.cms.gov/newsroom/fact-sheets/calendar-year-cy-2026-end-stage-renal-disease-esrd-prospective-payment-system-proposed-rule-cms-1830" target="_blank" rel="noreferrer noopener">Centers for Medicare &amp; Medicaid Services</a></li>



<li>Al-Haboubi M et al. <em>Public views on xenotransplantation from the first clinical successes</em>. <em>The Lancet</em>. 2025.<a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2825%2901195-X/fulltext" target="_blank" rel="noreferrer noopener">The Lancet</a></li>
</ol>



<p class="wp-block-paragraph"></p>
]]></content:encoded>
					
					<wfw:commentRss>https://naturenal.com/pig-kidney-transplant/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Powerful New Model for True CKD Remission: A Paradigm Shift in Chronic Kidney Disease Management.</title>
		<link>https://naturenal.com/ckd-remission/</link>
		
		<dc:creator><![CDATA[admin]]></dc:creator>
		<pubDate>Tue, 18 Nov 2025 23:32:28 +0000</pubDate>
				<category><![CDATA[CKD]]></category>
		<category><![CDATA[Innovations]]></category>
		<category><![CDATA[Kidney Wellness]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[chronic kidney disease]]></category>
		<category><![CDATA[CKD remission]]></category>
		<category><![CDATA[finerenone]]></category>
		<category><![CDATA[KDIGO CKD guideline]]></category>
		<category><![CDATA[kidney health]]></category>
		<category><![CDATA[patient engagement]]></category>
		<category><![CDATA[renal outcomes]]></category>
		<category><![CDATA[SGLT2 inhibitors]]></category>
		<category><![CDATA[Tangri remission model]]></category>
		<guid isPermaLink="false">https://naturenal.com/?p=1412</guid>

					<description><![CDATA[Chronic kidney disease (CKD) care is undergoing a fundamental transformation. For decades, clinicians framed CKD as a condition that could be slowed at best but rarely improved in any meaningful way. A recent publication in Kidney International by Tangri and colleagues challenges that long-held assumption and introduces a reproducible, evidence-based model for achieving CKD remission...]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">Chronic kidney disease (CKD) care is undergoing a fundamental transformation. For decades, clinicians framed CKD as a condition that could be slowed at best but rarely improved in any meaningful way. A recent publication in <em>Kidney International</em> by Tangri and colleagues challenges that long-held assumption and introduces a reproducible, evidence-based model for achieving <strong>CKD remission</strong> as a measurable state where albuminuria improves, kidney function stabilizes, and the trajectory of decline is no longer considered inevitable.</p>



<p class="wp-block-paragraph">This shift represents more than a theoretical refinement. It reframes what success looks like for patients, restructures how clinicians think about therapy, and aligns directly with the growing body of guideline-directed recommendations from KDIGO, KDOQI, and narrative reviews focused on disease-modifying therapies. Together, these sources build a unified case: <strong>CKD remission is possible, achievable, and quantifiable</strong>, and the tools to pursue it already exist in routine practice.</p>



<hr class="wp-block-separator has-alpha-channel-opacity"/>



<h2 class="wp-block-heading"><strong>Understanding the CKD Remission Framework</strong></h2>



<p class="wp-block-paragraph">The concept of <strong>CKD remission</strong> emphasizes a departure from older progression-only models. Traditional care typically measured success by slowing the rate of GFR decline. In contrast, the remission framework focuses on positive movement including reductions in albuminuria, stabilization of creatinine, and improvement in risk classification. This mirrors frameworks used in diabetes and heart failure, where therapeutic targets shifted over time from “delay deterioration” to “achieve meaningful recovery” or &#8220;stability over time.&#8221;</p>



<p class="wp-block-paragraph">Tangri et al. outline remission as a composite concept that includes:</p>



<ul class="wp-block-list">
<li>Sustained improvement in albuminuria categories</li>



<li>Stabilization or very slow decline in eGFR</li>



<li>Absence of acute kidney injury events</li>



<li>Optimization of guideline-based therapies</li>



<li>Demonstrable improvement in long-term risk profiles</li>
</ul>



<p class="wp-block-paragraph">This approach emphasizes proactive engagement with therapies known to influence glomerular hemodynamics, tubular workload, metabolic stress, and renal inflammation. It also builds on large trials showing that the modern interventions of RAAS blockade, SGLT2 inhibitors, and mineralocorticoid receptor antagonists can change the functional biology of kidney disease rather than merely delaying damage.</p>



<hr class="wp-block-separator has-alpha-channel-opacity"/>



<h2 class="wp-block-heading"><strong>What the Kidney International Article Demonstrates</strong></h2>



<p class="wp-block-paragraph">In the <em>Kidney International</em> report, Tangri and colleagues consolidate evidence that patients receiving comprehensive, layered therapy achieve remission markers far more frequently than previously recognized. They highlight data from recent trials showing significant reductions in albuminuria and improvements in clinical risk scores, especially with combined SGLT2 inhibitor and MRAs, and they describe remission as a “new standard of success” rather than an aspirational outcome.</p>



<p class="wp-block-paragraph">The key findings include:</p>



<ul class="wp-block-list">
<li>A growing proportion of patients exhibit <strong>meaningful improvement</strong> in albuminuria with optimized therapy.</li>



<li>SGLT2 inhibitors provide consistent reductions in CKD progression events across nearly all stages and risk categories.</li>



<li>Finerenone and related agents in the nonsteroidal MRA class add incremental protection beyond RAAS inhibition.</li>



<li>Early initiation of therapy correlates strongly with remission outcomes.</li>



<li>Remission aligns with reduced hospitalization rates, improved cardiovascular outcomes, and lower mortality.</li>
</ul>



<p class="wp-block-paragraph">These findings dovetail with real-world registries demonstrating that remission markers are associated with better long-term kidney survival than traditional stabilization goals.</p>



<hr class="wp-block-separator has-alpha-channel-opacity"/>



<h2 class="wp-block-heading"><strong>Why CKD Remission Is Clinically Important</strong></h2>



<p class="wp-block-paragraph">Reframing kidney care around <strong>CKD remission</strong> affects patients, clinicians, and health systems in several practical ways. It sets a higher bar which is evidence-based for what patients should expect from treatment. It reinforces the need for early diagnosis, home monitoring, and repeat albuminuria measurements. And it gives clinicians a structured target when adjusting medication regimens over months and years.</p>



<p class="wp-block-paragraph">Historically, education around CKD emphasized avoiding irreversible decline. Remission provides a different message: improvement is possible, and patients have an active role in helping therapies work effectively.</p>



<p class="wp-block-paragraph">For patients, remission often means:</p>



<div class="wp-block-group is-nowrap is-layout-flex wp-container-core-group-is-layout-8f761849 wp-block-group-is-layout-flex">
<ul class="wp-block-list">
<li>Fewer acute illness episodes</li>



<li>More stable blood pressure</li>



<li>Lower cardiovascular risk</li>



<li>Greater energy and functional capacity</li>



<li>Delayed or avoided dialysis</li>
</ul>



<figure class="wp-block-image size-full"><img decoding="async" width="400" height="400" src="https://naturenal.com/wp-content/uploads/2025/11/Remission-paradigm.webp" alt="" class="wp-image-1416" srcset="https://naturenal.com/wp-content/uploads/2025/11/Remission-paradigm.webp 400w, https://naturenal.com/wp-content/uploads/2025/11/Remission-paradigm-300x300.webp 300w, https://naturenal.com/wp-content/uploads/2025/11/Remission-paradigm-150x150.webp 150w, https://naturenal.com/wp-content/uploads/2025/11/Remission-paradigm-100x100.webp 100w" sizes="(max-width: 400px) 100vw, 400px" /></figure>
</div>



<p class="wp-block-paragraph">For clinicians, remission reshapes the conversation around long-term planning and risk communication, replacing therapeutic pessimism with realistic optimism.</p>



<hr class="wp-block-separator has-alpha-channel-opacity"/>



<h2 class="wp-block-heading"><strong>Where KDIGO 2024 Fits into the Remission Model</strong></h2>



<p class="wp-block-paragraph">The KDIGO 2024 CKD Guideline forms a foundational component of this modern framework. It emphasizes:</p>



<ul class="wp-block-list">
<li>Tight blood pressure control (target &lt;120 systolic when tolerated)</li>



<li>Routine measurement of albuminuria</li>



<li>Early deployment of disease-modifying therapies</li>



<li>Avoidance of nephrotoxins</li>



<li>Stage-specific medication stewardship</li>



<li>Aggressive cardiovascular risk reduction</li>
</ul>



<p class="wp-block-paragraph">Later parts of the guideline aligns directly with the remission concept by defining kidney-protective strategies that reduce proteinuria and slow eGFR decline. The language of “therapies that modify disease course” resonates clearly with Tangri’s remission framework.</p>



<p class="wp-block-paragraph">In essence: <strong>KDIGO provides the scaffolding; the remission model provides the target.</strong></p>



<hr class="wp-block-separator has-alpha-channel-opacity"/>



<h2 class="wp-block-heading"><strong>NKF and KDOQI: The U.S. Interpretation of Remission-Oriented CKD Care</strong></h2>



<p class="wp-block-paragraph">The KDOQI U.S. Commentary reinforces the importance of standardized measurement, early treatment uptake, and adherence to proven therapies. It highlights gaps in American implementation, acknowledging that many eligible patients never receive SGLT2 inhibitors or MRAs despite strong evidence of benefit.</p>



<p class="wp-block-paragraph">The Commentary also addresses real-world barriers (cost, polypharmacy, and concerns about side effects) and recommends system-level interventions that help clinicians sustain disease-modifying regimens long enough for remission markers to emerge.</p>



<p class="wp-block-paragraph">This perspective lends additional credibility and anchors the remission model within U.S. practice standards.</p>



<hr class="wp-block-separator has-alpha-channel-opacity"/>



<h2 class="wp-block-heading"><strong>How Patients Can Participate in CKD Remission</strong></h2>



<p class="wp-block-paragraph">Achieving <strong>CKD remission</strong> is not solely dependent on medication. Patients have critical influence over remission trajectories through daily habits and routine monitoring. Effective patient participation includes:</p>



<div class="wp-block-group is-nowrap is-layout-flex wp-container-core-group-is-layout-8f761849 wp-block-group-is-layout-flex">
<ul class="wp-block-list">
<li>Maintaining consistent blood pressure treatment</li>



<li>Following sodium-aware meal planning</li>



<li>Staying within prescribed hydration ranges</li>



<li>Avoiding NSAIDs</li>



<li>Monitoring home weight and symptoms</li>



<li>Bringing a structured CKD tracker to every appointment</li>
</ul>



<figure class="wp-block-image size-large is-resized"><img decoding="async" width="1024" height="683" src="https://naturenal.com/wp-content/uploads/2025/07/Wrist-BP-1024x683.png" alt="Patient arm with wrist blood pressure monitor, symbolizing CKD home monitoring" class="wp-image-493" style="width:320px;height:auto" srcset="https://naturenal.com/wp-content/uploads/2025/07/Wrist-BP-1024x683.png 1024w, https://naturenal.com/wp-content/uploads/2025/07/wrist-bp-rev-300x200.png 300w, https://naturenal.com/wp-content/uploads/2025/07/wrist-bp-rev-384x256.png 384w, https://naturenal.com/wp-content/uploads/2025/07/wrist-bp-rev-512x341.png 512w, https://naturenal.com/wp-content/uploads/2025/07/Wrist-BP-768x512.png 768w, https://naturenal.com/wp-content/uploads/2025/07/Wrist-BP-1320x880.png 1320w, https://naturenal.com/wp-content/uploads/2025/07/wrist-bp-rev.png 600w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
</div>



<p class="wp-block-paragraph">These steps reinforce medication effects and give clinicians reliable data to adjust therapy gradually rather than reactively.</p>



<p class="wp-block-paragraph">Learn how to be proactive in your CKD care by reading our <a href="/chronic-kidney-disease-faq-newly-diagnosed"><strong>CKD FAQ article</strong></a> with detailed links to more specific information.</p>



<hr class="wp-block-separator has-alpha-channel-opacity"/>



<h2 class="wp-block-heading"><strong>The Future of CKD Remission: Combining Therapies and Rethinking Outcomes</strong></h2>



<p class="wp-block-paragraph">The remission framework positions kidney care closer to cardiology and endocrinology, where combination therapy is now standard. The future likely includes:</p>



<ul class="wp-block-list">
<li>Broader use of SGLT2 inhibitors earlier in CKD</li>



<li>Increased adoption of finerenone</li>



<li>Integration of GLP-1 receptor agonists for metabolic risk</li>



<li>Risk-stratification using machine learning tools</li>



<li>Therapies targeting inflammation and fibrosis</li>



<li>Preventive strategies for high-risk stage 2 and 3 patients</li>
</ul>



<p class="wp-block-paragraph">This is a shift from “manage decline” to “optimize recovery,” and it resonates strongly with population health programs, value-based care initiatives, and proactive practice models.</p>



<hr class="wp-block-separator has-alpha-channel-opacity"/>



<h2 class="wp-block-heading"><strong>Conclusion</strong></h2>



<p class="wp-block-paragraph">The concept of <strong>CKD remission</strong> marks a major turning point in the management of chronic kidney disease. Supported by high-quality evidence from Tangri et al., reinforced by KDIGO 2024, and contextualized by the NKF/KDOQI U.S. commentary, remission reframes CKD from an unavoidably progressive disease into a treatable, modifiable condition with measurable targets.</p>



<p class="wp-block-paragraph">Patients benefit from a clearer sense of purpose. Clinicians gain a more precise therapeutic framework. And practice models that emphasize early therapy, structured follow-up, and evidence-based care will align naturally with this new paradigm.</p>



<p class="wp-block-paragraph">The message is simple and powerful: <strong>CKD remission is possible and increasingly expected when modern therapies and patient engagement work together.</strong></p>



<hr class="wp-block-separator has-alpha-channel-opacity"/>



<h1 class="wp-block-heading"><strong>Works Cited</strong></h1>



<ol class="wp-block-list">
<li><a href="https://www.kidney-international.org/article/S0085-2538(25)00847-6/fulltext" target="_blank" rel="noopener">Tangri N, Neuen BL, Cherney DZ, Tuttle KR, Perkovic V. <em>From Progression to Remission: A New Paradigm for Success in Chronic Kidney Disease.</em> Kidney International. 2025.</a></li>



<li><a href="https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf" target="_blank" rel="noopener">Kidney Disease: Improving Global Outcomes (KDIGO) 2024 CKD Guideline. <em>Kidney International.</em></a></li>



<li>Wanner C, et al. Guideline-Recommended Disease-Modifying Therapies for Chronic Kidney Disease: A Narrative Review. 2025.</li>



<li>KDOQI U.S. Commentary on the KDIGO 2024 CKD Guideline.</li>
</ol>



<p class="wp-block-paragraph"></p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Natural Kidney Cures Explained: What’s Safe, What’s Useless, and What Puts You at Risk</title>
		<link>https://naturenal.com/natural-kidney-cures-explained/</link>
		
		<dc:creator><![CDATA[admin]]></dc:creator>
		<pubDate>Sat, 29 Nov 2025 19:00:21 +0000</pubDate>
				<category><![CDATA[CKD]]></category>
		<category><![CDATA[Innovations]]></category>
		<category><![CDATA[Kidney Wellness]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Chronic Kidney Disease Education]]></category>
		<category><![CDATA[CKD Cures]]></category>
		<category><![CDATA[Herbal Supplements]]></category>
		<category><![CDATA[kidney wellness]]></category>
		<category><![CDATA[Natural Kidney Cures]]></category>
		<category><![CDATA[Patient Safety]]></category>
		<guid isPermaLink="false">https://naturenal.com/?p=1421</guid>

					<description><![CDATA[If you live with chronic kidney disease (CKD) or worry about your kidney health, you have probably searched online for “natural kidney cures.” The results are a wild mix of detox teas, miracle herbs, and expensive supplement stacks promising to “flush,” “repair,” or even “regrow” your kidneys. It’s no surprise that patients show up to...]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">If you live with chronic kidney disease (CKD) or worry about your kidney health, you have probably searched online for “natural kidney cures.” The results are a wild mix of detox teas, miracle herbs, and expensive supplement stacks promising to “flush,” “repair,” or even “regrow” your kidneys. It’s no surprise that patients show up to clinic carrying bottles and screenshots and asking what really helps.</p>



<p class="wp-block-paragraph">Here’s the unvarnished truth: there are <strong>no proven natural kidney cures</strong> that can reverse scarred kidney tissue or substitute for guideline-based CKD treatment. But there <em>are</em> natural habits and, in some cases, carefully chosen supplements that can safely support your overall health and help your prescribed therapies work better. On the other side, there are useless “natural kidney cures” that waste money and some that can seriously damage your kidneys or trigger acute kidney injury.</p>



<p class="wp-block-paragraph">This article breaks down natural kidney cures into three buckets: what is plausibly safe and helpful, what is mostly useless, and what is flat-out dangerous if you have CKD or are at high risk.</p>



<h2 class="wp-block-heading"><strong>Why “Natural” Is Not Automatically Kidney-Safe</strong></h2>



<p class="wp-block-paragraph">The phrase “natural kidney cures” sounds reassuring, but “natural” does <strong>not</strong> mean harmless, especially when your kidneys are already impaired. Most herbal products are regulated very differently from prescription drugs. They do not have to prove that they prevent CKD, reverse CKD, or even protect kidney function before going on the shelf. Doses can vary from batch to batch, ingredient lists may be incomplete, and contamination with heavy metals or other drugs is surprisingly common. (<a href="https://www.kidneynews.org/view/journals/kidney-news/16/8/article-p22_12.xml" target="_blank" rel="noreferrer noopener">Kidney News</a>)</p>



<p class="wp-block-paragraph">Major kidney organizations repeatedly caution patients with CKD to be careful with supplements and herbal remedies. The National Kidney Foundation and others highlight at least three key concerns: some herbs are directly toxic to kidney tissue, some build up in the body when kidney function is reduced, and many can interact with prescription medications in dangerous ways. (<a href="https://www.kidney.org/kidney-topics/herbal-supplements-and-kidney-disease" target="_blank" rel="noreferrer noopener">National Kidney Foundation</a>) In short, <strong>“natural kidney cures” can create very unnatural problems</strong> if they’re chosen blindly.</p>


<div class="wp-block-image">
<figure class="aligncenter size-full"><img decoding="async" width="600" height="400" src="https://naturenal.com/wp-content/uploads/2025/11/CKD-good-vs-bad.webp" alt="Illustration of a healthy kidney surrounded by simple icons for food, exercise, sleep, and medication, representing safe lifestyle habits that support kidney health.  Compares to non-FDA approved corruption in wellness space." class="wp-image-1428" srcset="https://naturenal.com/wp-content/uploads/2025/11/CKD-good-vs-bad.webp 600w, https://naturenal.com/wp-content/uploads/2025/11/CKD-good-vs-bad-300x200.webp 300w, https://naturenal.com/wp-content/uploads/2025/11/CKD-good-vs-bad-384x256.webp 384w, https://naturenal.com/wp-content/uploads/2025/11/CKD-good-vs-bad-512x341.webp 512w" sizes="(max-width: 600px) 100vw, 600px" /></figure>
</div>


<p class="wp-block-paragraph">At the same time, modern CKD guidelines emphasize that lifestyle changes, blood pressure control, diabetes management, and evidence-based medications (ACE inhibitors, ARBs, SGLT2 inhibitors, mineralocorticoid receptor antagonists, etc.) are what truly slow progression and, in some cases, achieve partial remission. (<a href="https://www.kidney-international.org/article/%20S0085-2538%2823%2900766-4/fulltext" target="_blank" rel="noopener">kidney-international.org</a>) Those tools are the backbone. Everything else – including any so-called natural kidney cures – has to be judged against that standard.</p>



<h2 class="wp-block-heading"><strong>Remedies with Plausible Benefit (and How to Use Them Safely)</strong></h2>



<p class="wp-block-paragraph">There is no magic smoothie, tea, or capsule that qualifies as a true natural kidney cure. But there <em>are</em> “low-drama” habits and carefully selected supports that align with CKD guidelines and may help protect overall health.</p>



<p class="wp-block-paragraph"><strong>1. A kidney-aware, plant-forward eating pattern</strong></p>



<p class="wp-block-paragraph">A thoughtful, kidney-aware version of the DASH or Mediterranean-style diet – adjusted for potassium, phosphorus, and protein based on your labs – is one of the most powerful “natural kidney cures” people actually control. A diet rich in vegetables, fruits within your potassium limits, whole grains in appropriate portions, healthy fats, and limited ultra-processed foods supports blood pressure, cardiovascular health, and metabolic balance. That, in turn, supports the kidneys. (<a href="https://naturenal.com/kidney-friendly-nutrition-what-to-eat-and-why/" target="_blank" rel="noreferrer noopener">Naturenal</a>)</p>



<p class="wp-block-paragraph">Instead of chasing single “superfoods,” it’s smarter to work with a renal dietitian to adapt a structured plan like a CKD-modified DASH diet. This helps you avoid the trap of “detox” juicing and unbalanced restrictive fads that claim to be natural kidney cures but ignore real-world lab constraints (for example, dangerous potassium loads). (<a href="https://naturenal.com/wp-content/uploads/2025/06/CKD-DASH-Diet.pdf" target="_blank" rel="noreferrer noopener">Naturenal</a>)</p>



<p class="wp-block-paragraph"><strong>2. Steady hydration – not “kidney flushes”</strong></p>



<p class="wp-block-paragraph">Unless your care team has told you to restrict fluids, staying reasonably hydrated supports normal kidney function, blood pressure, and concentration of waste products. But <strong>more is not always better</strong>. Aggressive “water challenges,” “kidney flushes,” or extreme fluid pushes marketed as natural kidney cures can dilute sodium, worsen heart failure, or backfire in later-stage CKD. Aim for consistent daily intake that fits your stage, heart function, and diuretic regimen – not social-media hydration stunts.</p>



<p class="wp-block-paragraph"><strong>3. Targeted vitamin D and bone–mineral support</strong></p>



<p class="wp-block-paragraph">Many people with CKD have low vitamin D levels. Replacing vitamin D under medical supervision is guideline-supported and may help bone health and secondary hyperparathyroidism. (<a href="https://www.kidney-international.org/article/%20S0085-2538%2823%2900766-4/fulltext?utm_source=chatgpt.com" target="_blank" rel="noreferrer noopener">kidney-international.org</a>) That does <strong>not</strong> mean megadose over-the-counter vitamin D or calcium qualifies as a natural kidney cure. Extra-large doses can raise calcium or phosphorus and accelerate vascular calcification. If vitamin D is used, it should be with lab monitoring and dose guidance from your kidney team.</p>



<p class="wp-block-paragraph"><strong>4. Omega-3 fatty acids for cardiovascular support</strong></p>



<p class="wp-block-paragraph">Omega-3 fatty acids from fatty fish (like salmon or sardines) or from high-quality, third-party-tested fish oil capsules may support triglyceride levels and cardiovascular health. Heart and kidney health are tightly linked, so this is sometimes framed online as one of the “natural kidney cures.” The more accurate framing: omega-3s support heart and vascular health, which <strong>indirectly</strong> supports people living with CKD. Dose, purity, and bleeding risk (especially if you take anticoagulants or antiplatelet agents) all matter (<a href="https://www.ahajournals.org/doi/full/10.1161/01.ATV.0000057393.97337.AE?uid=6767af34s16&amp;" target="_blank" rel="noopener">Circulation</a>).</p>



<p class="wp-block-paragraph"><strong>5. Movement, sleep, and weight management</strong></p>



<p class="wp-block-paragraph">Routine physical activity, better sleep, and thoughtful weight management are some of the most under-rated “natural kidney cures” because they’re not sold in a bottle. Regular movement improves blood pressure, insulin sensitivity, mood, and cardiovascular fitness. Prioritizing sleep supports hormonal balance and appetite regulation. Intentional weight loss in people with obesity and CKD can improve blood pressure and diabetes control. None of this regenerates scarred nephrons, but together it shifts the entire risk profile in your kidneys’ favor. (<a href="https://www.acpjournals.org/doi/10.7326/0003-4819-158-11-201306040-00007" target="_blank" rel="noreferrer noopener">American College of Physicians Journals</a>)</p>



<hr class="wp-block-separator has-alpha-channel-opacity"/>



<h2 class="wp-block-heading"><strong>Popular “Cures” That Don’t Help (But Drain Your Wallet)</strong></h2>



<p class="wp-block-paragraph">The next category includes products marketed loudly as natural kidney cures but lacking meaningful evidence of benefit. They’re not always overtly toxic, but they siphon money, attention, and hope.</p>



<p class="wp-block-paragraph"><strong>“Detox” teas and “kidney cleanse” kits</strong></p>



<p class="wp-block-paragraph">Many teas and cleanse products combine diuretic herbs (like dandelion, nettle, or parsley) with laxatives and vague promises to “flush toxins.” Your kidneys are already the detox system. Forcing extra urine output with unregulated herbal diuretics does <strong>not</strong> repair damage or improve filtration. In CKD, this kind of product can actually worsen dehydration, disrupt electrolytes, or interact with prescribed diuretics. Calling these natural kidney cures is misleading at best. (<a href="https://www.kidneyfund.org/treatments/medicines-kidney-disease/herbal-supplements-and-chronic-kidney-disease-ckd" target="_blank" rel="noreferrer noopener">American Kidney Fund</a>)</p>



<p class="wp-block-paragraph"><strong>Alkaline water and extreme pH diets</strong></p>



<p class="wp-block-paragraph">There is genuine scientific interest in dietary acid load and CKD progression, but that is not the same as selling alkaline water or pH gimmicks as natural kidney cures. Most people’s blood pH is tightly regulated by the lungs and kidneys; drinking expensive alkaline water does little to change that. Under normal physiologic conditions, the high acid environment in the stomach will buffer the alkaline content before it could be meaningfully absorbed.  A plant-forward, kidney-aware diet does far more to reduce net acid load than any specialty water.</p>



<p class="wp-block-paragraph"><strong>Unproven “kidney support” blends</strong></p>



<p class="wp-block-paragraph">Walk through a vitamin aisle and you’ll see capsules labeled for “kidney support,” “renal cleanse,” or “natural kidney cures.” The ingredient lists are often a grab bag of herbs with minimal human data in CKD – sometimes including ones that appear on nephrology “avoid” lists. Advertising language leans on vague phrases like “traditional use” while skipping over actual outcome data. If a product cannot point to controlled human trials showing slowed CKD progression, reduced albuminuria, or improved hard outcomes, it is <strong>not</strong> a proven natural kidney cure.</p>



<p class="wp-block-paragraph"><strong>Megadose single vitamins or minerals</strong></p>



<p class="wp-block-paragraph">Large doses of vitamin C, vitamin A, or certain minerals are often pitched as immune boosters or detoxifiers. In CKD, these can accumulate and cause harm. High-dose vitamin C can raise oxalate levels and has been linked to kidney stones and oxalate nephropathy in susceptible patients. Overshooting vitamin A can cause liver and bone toxicity. None of this qualifies as responsible use of natural kidney cures. (<a href="https://newsnetwork.mayoclinic.org/discussion/people-with-kidney-disease-should-be-cautious-with-supplementspeople-with-kidney-disease-should-be-cautious-with-supplements/" target="_blank" rel="noreferrer noopener">Mayo Clinic News Network</a>)</p>



<hr class="wp-block-separator has-alpha-channel-opacity"/>



<h2 class="wp-block-heading"><strong>Dangerous Ingredients That Can Worsen CKD or Trigger Acute Injury</strong></h2>



<p class="wp-block-paragraph">Some natural products are not just useless &#8211; they’re outright dangerous for the kidneys. These are the furthest thing from safe natural kidney cures.</p>



<p class="wp-block-paragraph">Today’s kidney wellness market has moved far beyond simple herbal teas. Patients are now targeted by polished “kidney detox” teas, 23-in-1 liver–kidney cleanse stacks, Ayurvedic and TCM “CKD reversal” programs, and social-media “no dialysis” success stories that funnel viewers into paid protocols. Major kidney organizations now explicitly advise people with CKD to avoid any product marketed as a “kidney detox” or “kidney cleanse,” because evidence is weak and some ingredients can directly injure the kidneys or interact with medications. <a href="https://www.kidney.org/kidney-topics/herbal-supplements-and-kidney-disease" target="_blank" rel="noreferrer noopener">(NKF/AKF 2024–2025)</a></p>



<p class="wp-block-paragraph">Below are the some of the most current advertising gimmicks:</p>



<p class="wp-block-paragraph"><span style="text-decoration: underline;">Hydrogen Water</span>: Hydrogen-enriched water is heavily promoted for “cellular repair,” but the physiology doesn’t support the claims. Molecular hydrogen (H₂) is poorly absorbed in the GI tract; most of it is simply belched or passed as gas, and the small amount that enters circulation is largely inert. No human studies show improvements in eGFR, albuminuria, or CKD progression. For kidney patients, hydrogen water is not harmful but not helpful and is merely a hydration variant with no proven renal benefit and marketing claims that far exceed the science.</p>



<p class="wp-block-paragraph"><span style="text-decoration: underline;">Kidney detox / kidney cleanse teas and capsules</span>:  Multi-herb blends sold as organ flushes. Multi-herb tea blends marketed as “kidney detox” or “kidney cleanse.” Often include herbs like dandelion, nettle, horsetail, uva ursi, datura, cape aloe and parsley root. NKF and AKF now explicitly warn CKD patients to avoid these because ingredients can be nephrotoxic or interact with prescription drugs. They do not repair damaged kidneys or slow CKD progression.</p>



<p class="wp-block-paragraph"><span style="text-decoration: underline;">Multi-ingredient liver–kidney detox stacks </span>: 20+ ingredients with several herbs on CKD &#8220;avoid&#8221; lists. Commonly mix cordyceps, bupleurum, rehmannia, “stone breaker,” cornsilk, nettle, uva ursi, parsley root, and other herbs now listed on CKD “avoid” lists. Regulation is poor and kidney outcomes have not been proven in controlled trials</p>



<p class="wp-block-paragraph"><span style="text-decoration: underline;">Ayurvedic / TCM “reversal” clinics and online programs</span>: promising to reverse CKD or replace dialysis. Ayurvedic and TCM clinic are online programs claiming to &#8216;reverse kidney disease&#8217; or replace dialysis with herbs and detox regimens. Evidence is weak and some preparations carry contamination or nephrotoxicity risks.</p>



<p class="wp-block-paragraph"><span style="text-decoration: underline;">Social-media “no dialysis” miracle protocols</span>: reels and shorts claiming complete natural reversal. YouTube, TikTok, and Instagram reels where individuals claim they “reversed kidney failure” or “avoided dialysis” by stopping medications and using secret diets, teas, or supplement stacks. These stories are impossible to verify, ignore competing medical explanations, and can push patients to abandon therapies that actually improve survival.</p>



<p class="wp-block-paragraph"><span style="text-decoration: underline;">Rebranded basics</span>: alkaline water, generic multivitamins, probiotics, collagen, or water filters sold as kidney cures despite no CKD-specific data. Standard low-risk products including daily multivitamins, generic probiotics, collagen powder, simple water filters repackaged as kidney detox solutions. In usual doses they may not complicate core kidney problem, but they also do not reverse CKD or substitute for guideline-based therapy, despite the branding.</p>



<p class="wp-block-paragraph">On the surface these may look very different, but under the hood they share the same pattern: implied cure, vague science, and very real risk once CKD and polypharmacy are in the picture.  Beware of subjective testimonials and marketing pitches being misrepresented as clinical fact.</p>



<p class="wp-block-paragraph"><strong>1. Aristolochia and aristolochic acid</strong></p>



<p class="wp-block-paragraph">Herbal remedies containing aristolochic acid (often from <em>Aristolochia</em> species in some traditional blends) are strongly linked to “aristolochic acid nephropathy” which is a rapidly progressive, scarring kidney disease that can lead to kidney failure and even urothelial cancer. (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10565449/?utm_source=chatgpt.com" target="_blank" rel="noopener">PMC</a>) Even relatively short-term exposure has been associated with irreversible damage. Several countries have banned these products, yet they still appear in some online formulations marketed as detox or slimming cures. Nothing containing <em>Aristolochia</em> belongs anywhere near a person concerned about kidney health.</p>



<p class="wp-block-paragraph"><strong>2. High-risk herbs on CKD “avoid” lists</strong></p>



<p class="wp-block-paragraph">The National Kidney Foundation and other groups have identified multiple herbs that are potentially harmful in CKD, either because they are directly nephrotoxic or because they affect blood pressure, electrolytes, or drug metabolism. Examples include licorice root (which can raise blood pressure and lower potassium), barberry, goldenrod, nettle, horsetail, cat’s claw, Java tea leaf, astragalus, uva ursi and others. (<a href="https://www.kidneyfund.org/treatments/medicines-kidney-disease/herbal-supplements-and-chronic-kidney-disease-ckd" target="_blank" rel="noreferrer noopener">American Kidney Fund</a>) These sometimes show up inside blends promoted as natural kidney cures, which makes them even more concerning.</p>



<p class="wp-block-paragraph"><strong>3. Non-prescription NSAID-like botanicals</strong></p>



<p class="wp-block-paragraph">Products containing willow bark or other salicylate-rich herbs are often marketed as “natural pain relief.” Pharmacologically, they behave a lot like nonsteroidal anti-inflammatory drugs (NSAIDs), which are known to reduce blood flow into the kidney’s filtering units and increase the risk of acute kidney injury especially in people taking diuretics, ACE inhibitors, or ARBs. Slipping these into a regimen of natural kidney cures can quietly sabotage otherwise careful CKD management. (<a href="https://kdigo.org/wp-content/uploads/2019/01/KDIGO-2012-AKI-Guideline-English.pdf" target="_blank" rel="noreferrer noopener">KDIGO</a>)</p>



<p class="wp-block-paragraph"><strong>4. High-potassium “super-juices” and tonics</strong></p>



<p class="wp-block-paragraph">Noni juice, certain concentrated vegetable juices (including beet juice), and some “superfood” blends can contain very high amounts of potassium. For someone with advanced CKD, potassium levels can rise quickly and unpredictably, leading to dangerous heart rhythm disturbances. Labeling a high-potassium tonic as a natural kidney cure ignores basic physiology.</p>



<p class="wp-block-paragraph"><strong>5. Bodybuilding, weight-loss, and “energy” boosters</strong></p>



<p class="wp-block-paragraph">Many weight-loss, pre-workout, and bodybuilding supplements are packed with stimulants, unlisted pharmaceuticals, or high-dose ingredients that can strain both the heart and kidneys. People with CKD are often specifically advised by kidney organizations to avoid these categories altogether. (<a href="https://www.kidney.org/news-stories/8-key-things-to-know-taking-supplements" target="_blank" rel="noreferrer noopener">National Kidney Foundation</a>) They are the opposite of safe natural kidney cures.</p>



<hr class="wp-block-separator has-alpha-channel-opacity"/>



<h2 class="wp-block-heading"><strong>Red-Flag Botanicals for Non-Kidney Ailments (Still Harmful in CKD)</strong></h2>



<p class="wp-block-paragraph">A subtle trap is using natural products for problems that are not obviously kidney-related – headaches, colds, joint pain, anxiety – without realizing that those products can still stress your kidneys. These are not marketed as natural kidney cures, but they show up frequently in the medicine cabinets of people with CKD.</p>



<ul class="wp-block-list">
<li><strong>Willow bark and other “natural aspirin” products</strong><br>As noted, willow bark behaves like an NSAID. Using it regularly for headaches, arthritis, or back pain can create the same kidney risks as chronic ibuprofen or naproxen use.</li>



<li><strong>Licorice root for reflux or adrenal “support”</strong><br>Licorice root appears in teas, candies, and supplements marketed for digestion or “adrenal fatigue.” In higher doses or prolonged use, it can cause sodium retention, low potassium, and high blood pressure – all bad news for CKD.</li>



<li><strong>Noni juice and high-potassium wellness shots</strong><br>These are often advertised as immune or anti-inflammatory boosters, not as natural kidney cures. In CKD, they can quietly push potassium into the danger zone.</li>



<li><strong>“Immune booster” blends with multiple herbs</strong><br>Ginseng, ginkgo, garlic, and other herbs with anticoagulant or blood-pressure effects can be problematic in CKD, especially in people on blood thinners or antiplatelet drugs. When taken together in unregulated “immune blends,” their combined impact is unpredictable. (<a href="https://kidneyhi.org/blog/herbal-supplements-and-ckd/" target="_blank" rel="noreferrer noopener">National Kidney Foundation</a>)</li>
</ul>



<p class="wp-block-paragraph">The practical message: even if a product is <strong>not</strong> sold as a natural kidney cure, it may still deserve a call to your nephrologist or pharmacist before you use it.</p>



<hr class="wp-block-separator has-alpha-channel-opacity"/>



<h2 class="wp-block-heading"><strong>How to Vet Supplements: A Quick Patient Checklist</strong></h2>



<p class="wp-block-paragraph">Given all this noise, how do you evaluate the next “natural kidney cures” ad that crosses your screen? A simple checklist helps:</p>



<div class="wp-block-group is-nowrap is-layout-flex wp-container-core-group-is-layout-e148e5c0 wp-block-group-is-layout-flex">
<figure class="wp-block-image size-full is-resized"><img decoding="async" width="300" height="450" src="https://naturenal.com/wp-content/uploads/2025/11/vetting-sequence.webp" alt="" class="wp-image-1427" style="width:215px;height:auto" srcset="https://naturenal.com/wp-content/uploads/2025/11/vetting-sequence.webp 300w, https://naturenal.com/wp-content/uploads/2025/11/vetting-sequence-200x300.webp 200w" sizes="(max-width: 300px) 100vw, 300px" /></figure>



<ul class="wp-block-list">
<li><strong>Start with your diagnosis and stage.</strong><br>The same product can pose different risks in Stage 2 vs Stage 4 CKD, in transplant recipients, or in people on dialysis.</li>



<li><strong>Check for third-party testing.</strong><br>Look for certifications that test for purity and label accuracy – they’re not perfect, but they’re better than nothing.</li>



<li><strong>Search for real human data, not just testimonials.</strong><br>Does the product have any controlled studies in CKD or even in high-risk populations? Or just before-and-after photos and anonymous reviews?</li>



<li><strong>Cross-check with trusted kidney resources.</strong><br>See whether ingredients appear on “avoid” lists from major kidney organizations, or whether there are warnings in reputable CKD patient-education materials. (<a href="https://www.kidney.org/kidney-topics/herbal-supplements-and-kidney-disease" target="_blank" rel="noreferrer noopener">National Kidney Foundation</a>)</li>



<li><strong>Review your entire regimen with your care team.</strong><br>Bring all bottles, powders, and teas – including those you think are harmless. Interactions often show up only when everything is seen together.</li>



<li><strong>Let labs guide decisions.</strong><br>If you and your nephrologist decide to try a supplement for a specific reason, there should be a plan: which labs to follow, what would count as benefit, and when to stop.</li>
</ul>
</div>



<p class="wp-block-paragraph">This mindset turns random hunting for natural kidney cures into a structured, safety-first conversation.</p>



<hr class="wp-block-separator has-alpha-channel-opacity"/>



<h2 class="wp-block-heading"><strong>Working with Your Care Team: Integrating Evidence-Based Lifestyle Changes</strong></h2>



<p class="wp-block-paragraph">Instead of chasing miracle natural kidney cures, it is far more powerful to integrate kidney-aware lifestyle changes into the same framework your nephrologist already uses to slow CKD or aim for remission. That means:</p>



<ul class="wp-block-list">
<li>Hitting blood pressure targets and monitoring at home. (<a href="https://naturenal.com/high-blood-pressure-and-kidney-disease/">Naturenal</a>)</li>



<li>Using guideline-supported medications to reduce proteinuria and protect the kidneys. (<a href="https://www.kidney-international.org/article/%20S0085-2538%2823%2900766-4/fulltext" target="_blank" rel="noreferrer noopener">kidney-international.org</a>)</li>



<li>Adapting your diet with a renal dietitian rather than experimenting alone. (<a href="https://naturenal.com/kidney-friendly-nutrition-what-to-eat-and-why/">Naturenal</a>)</li>



<li>Tracking labs and symptoms over time, ideally with a dedicated CKD tracker. (<a href="https://naturenal.com/chronic-kidney-disease-faq-newly-diagnosed/">Naturenal</a>)</li>



<li>Addressing sleep, stress, and movement in realistic, sustainable ways. (<a href="https://www.nature.com/articles/nrneph.2016.148?utm_source=chatgpt.com" target="_blank" rel="noopener">Nature</a>)</li>
</ul>



<p class="wp-block-paragraph">Resources on topics like blood pressure and kidney disease, kidney-friendly nutrition, and CKD remission provide a more reliable roadmap than any single supplement. Articles such as <a href="https://naturenal.com/high-blood-pressure-and-kidney-disease/">High Blood Pressure and Kidney Disease: 5 Ways to Change for the Better</a>, <a href="https://naturenal.com/kidney-friendly-nutrition-what-to-eat-and-why/">Improve Your Diet: The Impact of Nutritional Focus on Preserving Kidney Function</a>, and <a href="https://naturenal.com/ckd-remission">Powerful New Model for True CKD Remission: A Paradigm Shift in Chronic Kidney Disease Care</a> show how lifestyle, medications, and close follow-up work together – instead of promising a one-bottle solution. (<a href="https://naturenal.com/high-blood-pressure-and-kidney-disease/">Naturenal</a>)</p>



<hr class="wp-block-separator has-alpha-channel-opacity"/>



<h2 class="wp-block-heading"><strong>Key Takeaways: Safe Habits vs. Risky Shortcuts</strong></h2>



<p class="wp-block-paragraph">When you strip away the marketing language, most so-called natural kidney cures fall into one of three categories:</p>


<div class="wp-block-image">
<figure class="aligncenter size-full"><img decoding="async" width="600" height="400" src="https://naturenal.com/wp-content/uploads/2025/11/kidney-wellness-risk-continuum.webp" alt="" class="wp-image-1426" srcset="https://naturenal.com/wp-content/uploads/2025/11/kidney-wellness-risk-continuum.webp 600w, https://naturenal.com/wp-content/uploads/2025/11/kidney-wellness-risk-continuum-300x200.webp 300w, https://naturenal.com/wp-content/uploads/2025/11/kidney-wellness-risk-continuum-384x256.webp 384w, https://naturenal.com/wp-content/uploads/2025/11/kidney-wellness-risk-continuum-512x341.webp 512w" sizes="(max-width: 600px) 100vw, 600px" /></figure>
</div>


<ul class="wp-block-list">
<li><strong>Aligned with good care:</strong><br>Kidney-aware nutrition, appropriate hydration, movement, sleep, and carefully monitored correction of deficiencies (like vitamin D) can quietly support long-term kidney health.</li>



<li><strong>Neutral but distracting:</strong><br>Many cleanse kits, teas, and “kidney support” blends are more about branding than biology. They may not only harm directly, but they also siphon money and focus away from things that truly matter.</li>



<li><strong>Actively harmful:</strong><br>Aristolochic acid–containing herbs, licorice, certain high-risk botanicals, high-potassium tonics, and bodybuilding or weight-loss supplements can accelerate kidney damage or trigger acute injury.</li>
</ul>



<p class="wp-block-paragraph">The goal is not to ban every herbal or natural product from your life. It’s to <strong>stop thinking in terms of secret natural kidney cures</strong> and start thinking in terms of a coherent kidney-protection plan. Real progress in CKD usually comes from aligning everyday choices with proven therapies – not from whatever happens to be trending on social media this month.</p>



<hr class="wp-block-separator has-alpha-channel-opacity"/>



<h2 class="wp-block-heading"><strong>References</strong></h2>



<ol start="1" class="wp-block-list">
<li>Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. <em>Kidney International</em>. 2024;105(4S):S117–S314. (<a href="https://www.kidney-international.org/article/%20S0085-2538%2823%2900766-4/fulltext" target="_blank" rel="noreferrer noopener">kidney-international.org</a>)</li>



<li>National Kidney Foundation. Herbal Supplements and Kidney Disease. Accessed 2025. (<a href="https://www.kidney.org/kidney-topics/herbal-supplements-and-kidney-disease" target="_blank" rel="noreferrer noopener">National Kidney Foundation</a>)</li>



<li>Jain A, et al. Herbal nephropathy: an update on the nephrotoxic effects of herbal medicines. <em>Kidney International Reports</em>. 2019;4(12):1628–1633. (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6822647/" target="_blank" rel="noreferrer noopener">PMC</a>)</li>



<li>Zhou Q, et al. Overview of aristolochic acid nephropathy: an update. <em>Kidney International</em>. 2023;103(6):1135–1147. (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10565449/" target="_blank" rel="noreferrer noopener">PMC</a>)</li>



<li>Xu X, et al. Nephrotoxicity of herbal medicine and its prevention. <em>Frontiers in Pharmacology</em>. 2020;11:569551. (<a href="https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.569551/full" target="_blank" rel="noreferrer noopener">Frontiers</a>)</li>
</ol>



<hr class="wp-block-separator has-alpha-channel-opacity"/>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Why Is My Blood Pressure Uncontrolled? Understanding Resistant and Secondary Hypertension</title>
		<link>https://naturenal.com/resistant-and-secondary-hypertension/</link>
		
		<dc:creator><![CDATA[admin]]></dc:creator>
		<pubDate>Wed, 28 Oct 2026 11:06:00 +0000</pubDate>
				<category><![CDATA[Hypertension]]></category>
		<category><![CDATA[Innovations]]></category>
		<category><![CDATA[blood pressure treatment]]></category>
		<category><![CDATA[CKD]]></category>
		<category><![CDATA[hypertension guidelines]]></category>
		<category><![CDATA[interventional hypertension]]></category>
		<category><![CDATA[potassium]]></category>
		<category><![CDATA[refractory hypertension]]></category>
		<category><![CDATA[resistant hypertension]]></category>
		<category><![CDATA[sodium]]></category>
		<category><![CDATA[uncontrolled hypertension]]></category>
		<guid isPermaLink="false">https://naturenal.com/?p=1684</guid>

					<description><![CDATA[Blood pressure that stays high despite several medications may be resistant hypertension. Learn how clinicians confirm it, find hidden causes, and treat them.]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">You take your medications. You&#8217;ve watched the salt. And still, when you sit down in the clinic, that top number is stubbornly above where it should be for you. If this sounds familiar, you&#8217;re not alone, and it doesn&#8217;t mean you&#8217;re doing something wrong.</p>



<p class="wp-block-paragraph">It does mean it&#8217;s time to look closer. High blood pressure that stays above goal despite several medications get special consideration and in some people, there is an underlying cause that can be found and treated.  These situations are coined <strong>resistant and secondary hypertension</strong>, respectively.</p>



<h2 class="wp-block-heading">What Resistant Hypertension Actually Means</h2>



<p class="wp-block-paragraph">Hypertension is high blood pressure, a sustained force against your artery walls that can damage the heart, brain, kidneys, and eyes over time. For most people, one or two medications plus lifestyle changes are enough; for some, they&#8217;re not.</p>



<p class="wp-block-paragraph">Clinicians use a specific definition of resistant hypertension: <strong>blood pressure remains above goal despite three complementary antihypertensive medications at maximally tolerated doses, including an appropriate diuretic (a &#8220;water pill&#8221;), or four or more medications are needed to achieve control.</strong></p>



<p class="wp-block-paragraph">Simply taking several pills doesn&#8217;t qualify, nor does one high reading. The label matters because it triggers a specific next step: confirm the resistance is real, then look for secondary causes. Four related terms help:</p>



<ul class="wp-block-list">
<li><strong>Uncontrolled hypertension</strong> : blood pressure above goal, whatever the cause.</li>



<li><strong>Apparent treatment-resistant hypertension</strong> : readings that <em>look</em> resistant but may be explained by measurement issues, white-coat effect, or missed doses.</li>



<li><strong>True resistant hypertension</strong> : confirmed high out-of-office blood pressure despite verified optimal therapy.</li>



<li><strong>Secondary hypertension</strong> : high blood pressure from an identifiable underlying condition (kidney disease, a hormone problem, a narrowed artery) rather than the usual mix of genes and lifestyle (&#8220;primary&#8221; or &#8220;essential&#8221;).</li>
</ul>



<h2 class="wp-block-heading">First: Make Sure It&#8217;s Truly Resistant</h2>



<p class="wp-block-paragraph">Before labeling blood pressure &#8220;resistant,&#8221; it&#8217;s worth ruling out what doctors call <strong>pseudoresistance</strong>, when the numbers look uncontrolled but the real problem is simpler to fix. Common contributors:</p>



<ul class="wp-block-list">
<li><strong>Measurement error.</strong> A cuff that&#8217;s too small, an unsupported arm, talking during the reading, or an uncalibrated machine can all push readings up.</li>



<li><strong>White-coat effect.</strong> Blood pressure rises in clinical settings for many people even when it&#8217;s normal at home.</li>



<li><strong>Missed doses.</strong> Forgetting pills, or stopping them because of side effects, is one of the most common reasons blood pressure stays high.</li>



<li><strong>Submaximal doses or mismatched combinations.</strong> Low doses of several drugs often work less well than a maximally tolerated regimen, and some pairings simply don&#8217;t complement each other.</li>



<li><strong>Interfering medications and substances.</strong> NSAID pain relievers (ibuprofen, naproxen), decongestants containing pseudoephedrine, stimulants, some herbal products such as licorice, and heavy alcohol use can all raise blood pressure or blunt medication effects.</li>



<li><strong>Excess dietary sodium.</strong> Salt is the most common dietary driver of treatment resistance, and it matters even more if you have kidney disease.</li>
</ul>



<p class="wp-block-paragraph">Home blood-pressure monitoring with a validated cuff gives your care team a truer picture than any single office visit. <strong>Ambulatory blood-pressure monitoring (ABPM)</strong>, a wearable device that measures pressure automatically over 24 hours, can confirm the pattern and rule out white-coat or &#8220;masked&#8221; hypertension.</p>



<h2 class="wp-block-heading">When to Look for a Secondary Cause</h2>



<p class="wp-block-paragraph">True resistant hypertension is a strong signal that an underlying cause may be at work; guidelines recommend looking for it, because finding the cause often changes treatment, sometimes dramatically. Secondary hypertension fall into these main categories:</p>



<ul class="wp-block-list">
<li><strong>Primary aldosteronism</strong> : excess production of a hormone called aldosterone (covered next)</li>



<li><strong>Kidney parenchymal disease / chronic kidney disease (CKD)</strong> : damaged filtering units retain salt and water</li>



<li><strong>Obstructive sleep apnea (OSA)</strong> : repeated nighttime breathing pauses keep the nervous system on high alert, raising pressure</li>



<li><strong>Renovascular disease</strong> : narrowing of one or both kidney arteries (covered below)</li>



<li><strong>Medication or substance causes</strong> : including some prescription drugs, over-the-counter products, and supplements</li>
</ul>



<p class="wp-block-paragraph">Less common endocrine and vascular causes exist too (Cushing&#8217;s syndrome, pheochromocytoma, thyroid disorders), considered when symptoms point that way. The key point: you don&#8217;t need every test; your care team uses your history, exam, labs, and blood-pressure pattern to choose what makes sense for <em>you</em>.</p>



<h2 class="wp-block-heading">Primary Aldosteronism: The Most Common Hidden Cause</h2>



<p class="wp-block-paragraph">Aldosterone is a hormone from the adrenal glands atop your kidneys that helps regulate salt and fluid balance, but when too much is produced, the kidneys hold onto sodium (and water), potassium can fall, and blood pressure climbs. <strong>Primary aldosteronism</strong> means the adrenals overproduce it on their own.</p>



<p class="wp-block-paragraph">It&#8217;s now recognized as the most common cause of secondary hypertension, and it&#8217;s under-recognized in resistant cases. Studies suggest it may account for up to about 20–30% of people with resistant hypertension; the 2025 AHA/ACC guideline recommends screening all such patients for excess aldosterone, <strong>even when potassium is normal</strong>.</p>



<p class="wp-block-paragraph">Two points matter most:</p>



<ol class="wp-block-list">
<li><strong>You don&#8217;t need low potassium to have it.</strong> Low potassium is a classic clue, but many people with primary aldosteronism have normal potassium, which is exactly why &#8220;screen only if potassium is low&#8221; misses so many cases.</li>



<li><strong>It&#8217;s treatable.</strong> Treatment depends on whether one or both glands are overactive: surgery for a single adenoma, or medication that blocks aldosterone&#8217;s effects, such as spironolactone.</li>
</ol>



<p class="wp-block-paragraph">Screening typically starts with an <strong>aldosterone-renin ratio</strong> blood test, followed by confirmatory testing if indicated; the 2025 Endocrine Society guideline even suggests considering screening in all people with high blood pressure, not just resistant cases. If your numbers are hard to control, this is a reasonable conversation.</p>



<h2 class="wp-block-heading">Kidney Disease Relationship to Resistant and Secondary Hypertension</h2>



<p class="wp-block-paragraph">High blood pressure and chronic kidney disease feed each other: damaged kidneys retain salt and water and overactivate the hormone system that raises pressure, while uncontrolled pressure accelerates kidney damage. If you live with CKD, your goals may be more specific: the KDIGO 2021 guideline suggests a systolic (top number) target <strong>below 120 mmHg when tolerated</strong>, measured using standardized office technique.</p>



<p class="wp-block-paragraph"><strong>IMPORTANT:</strong> For people with CKD and <a href="https://naturenal.com/proteinuria-basics/">protein in the urine (albuminuria)</a>, an ACE inhibitor or ARB is generally recommended even at normal blood pressure, but these medicines require monitoring of kidney function and potassium after starting or adjusting doses. Your nephrologist will set your personal target based on your stage, labs, and tolerance.</p>



<p class="wp-block-paragraph">For a deeper look at how these conditions interact, see our articles on <a href="https://naturenal.com/high-blood-pressure-and-kidney-disease/">high blood pressure and kidney disease</a> and <a href="https://naturenal.com/blood-pressure-vs-chronic-kidney/">blood pressure vs. chronic kidney disease</a>. Understanding your numbers, including what GFR means (<a href="https://naturenal.com/what-is-gfr-in-ckd/">what is GFR in CKD?</a>), makes these conversations easier.</p>



<h2 class="wp-block-heading">Renovascular Hypertension: When Narrowing of a Kidney Artery Matters</h2>



<p class="wp-block-paragraph">Each kidney receives its blood from a single renal artery branching off the aorta, the body&#8217;s main artery. <strong>Renovascular hypertension</strong> occurs when one or both of those arteries narrows, <strong>renal artery stenosis</strong> , reducing blood flow to the kidney. Sensing low perfusion, the kidney releases renin and sets off the <strong>renin-angiotensin-aldosterone system (RAAS)</strong>, a hormone cascade that constricts vessels and promotes sodium retention, producing high blood pressure driven by the kidney itself.</p>



<p class="wp-block-paragraph">There are two main types of renal artery narrowing:</p>



<ul class="wp-block-list">
<li><strong>Atherosclerotic renal artery stenosis</strong> : plaque buildup, the same process that narrows heart and leg arteries. More common in older adults with cardiovascular risk factors such as smoking, diabetes, or high cholesterol.</li>



<li><strong>Fibromuscular dysplasia (FMD)</strong> : a non-atherosclerotic condition causing abnormal development of the artery wall, often producing a &#8220;string-of-beads&#8221; appearance on imaging. It tends to affect younger women and follows different treatment logic than atherosclerotic disease.</li>
</ul>



<p class="wp-block-paragraph">Clues that may raise suspicion include:</p>



<ul class="wp-block-list">
<li>Sudden onset or marked worsening of previously well-controlled blood pressure</li>



<li>Resistant hypertension despite appropriate therapy</li>



<li>Otherwise unexplained decline in kidney function</li>



<li>A significant drop in kidney function after starting or intensifying an ACE inhibitor or ARB (in the right clinical context)</li>



<li>Recurrent sudden-onset pulmonary edema (&#8220;flash&#8221; heart-failure episodes)</li>



<li>Kidneys of noticeably different sizes on imaging, or a whooshing sound (bruit) heard over the abdomen</li>
</ul>



<p class="wp-block-paragraph"><strong>Important:</strong> not everyone with resistant hypertension needs renal-artery imaging; your clinician weighs these clues against the whole picture before ordering tests such as ultrasound, CT/MR angiography, or catheter-based angiography.</p>


<div class="wp-block-image">
<figure class="aligncenter size-full"><img decoding="async" width="500" height="500" src="https://naturenal.com/wp-content/uploads/2025/08/Renal-angio.webp" alt="A renal angiogram (catheter-based X-ray) showing blood flow through the kidney arteries" class="wp-image-1192" srcset="https://naturenal.com/wp-content/uploads/2025/08/Renal-angio.webp 500w, https://naturenal.com/wp-content/uploads/2025/08/Renal-angio-300x300.webp 300w, https://naturenal.com/wp-content/uploads/2025/08/Renal-angio-150x150.webp 150w, https://naturenal.com/wp-content/uploads/2025/08/Renal-angio-100x100.webp 100w" sizes="(max-width: 500px) 100vw, 500px" /><figcaption class="wp-element-caption">A renal angiogram (catheter-based X-ray) shows blood flow through the kidney arteries and can reveal narrowing.</figcaption></figure>
</div>


<h2 class="wp-block-heading">Why a Narrowed Artery Does NOT Automatically Mean a Stent</h2>



<p class="wp-block-paragraph">For decades, the reflex was to open any narrowed renal artery with a balloon and stent. Two large randomized trials changed that: <strong>CORAL</strong> (2014) and <strong>ASTRAL</strong> found that for most people with atherosclerotic renal artery stenosis, adding stenting to optimal medical therapy did not improve blood-pressure control or kidney outcomes versus medical therapy alone.</p>



<p class="wp-block-paragraph">That doesn&#8217;t mean the narrowed artery can be ignored; it means <strong>medical therapy is first-line</strong> for atherosclerotic disease:</p>



<ul class="wp-block-list">
<li>Aggressive cardiovascular risk management: statins for cholesterol, antiplatelet therapy (often aspirin), and smoking cessation</li>



<li>Standard antihypertensive treatment, often including an ACE inhibitor or ARB, valuable here but requiring monitoring of potassium and kidney function after starting or dose changes</li>
</ul>



<h2 class="wp-block-heading">When Renal-Artery Intervention May Still Help</h2>



<p class="wp-block-paragraph">Revascularization, opening the artery with angioplasty (balloon dilation), with or without a stent, remains important for <strong>selected</strong> patients. Referral may be reasonable when:</p>



<ul class="wp-block-list">
<li>Genuinely resistant hypertension that persists despite optimal medical therapy</li>



<li>Progressive kidney-function decline in a setting consistent with reduced blood flow to the kidney</li>



<li>Recurrent flash pulmonary edema or acute heart-failure episodes</li>
</ul>



<p class="wp-block-paragraph">When both arteries are significantly narrowed, or there is only one functioning kidney, the calculus changes. Those kidneys rely heavily on the narrowed vessels and RAAS-driven pressure to keep filtering; ACE inhibitors/ARBs carry higher risk of kidney-function decline there, so intervention needs careful individualized assessment by a vascular specialist.</p>



<p class="wp-block-paragraph">FMD deserves its own note: because it is a different disease in younger patients without widespread atherosclerosis, balloon angioplasty (usually <em>without</em> stenting) has a more favorable role; many people with FMD achieve blood-pressure control or even cure after successful dilation. The &#8220;stents don&#8217;t help&#8221; conclusion from the atherosclerotic trials does not apply to FMD.</p>



<h2 class="wp-block-heading">Standard Treatment Before Newer Therapies</h2>



<p class="wp-block-paragraph">Before reaching for newer options, guidelines emphasize optimizing the foundation: three complementary drug classes</p>



<ol class="wp-block-list">
<li><strong>ACE inhibitor or ARB</strong> (blocks RAAS)</li>



<li><strong>Calcium-channel blocker</strong> (relaxes blood vessels)</li>



<li><strong>Effective diuretic therapy</strong> (removes excess salt and water)</li>
</ol>



<p class="wp-block-paragraph">Two refinements matter here. First, thiazide-like diuretics such as chlorthalidone or indapamide are often preferred over short-acting alternatives because of their longer duration and stronger outcome evidence, though the right choice depends on your kidney function; when eGFR (estimated glomerular filtration rate) is low, loop diuretics like furosemide work better. See our guide to <a href="https://naturenal.com/diuretics-in-ckd/">diuretics in CKD</a>.</p>



<p class="wp-block-paragraph">Second, once three drugs are at work, <strong>spironolactone</strong> , which blocks aldosterone&#8217;s receptor , is the best-studied add-on: in the PATHWAY-2 trial it lowered home systolic blood pressure about 8.7 mmHg more than placebo over roughly three months, outperforming two other common add-ons (doxazosin and bisoprolol).</p>



<p class="wp-block-paragraph">If you have CKD, potassium monitoring becomes central: ACE inhibitors, ARBs, and spironolactone can all raise potassium, and your nephrologist or renal dietitian may customize the combination to match your stage and labs. Sodium reduction remains one of the most underused &#8220;medications&#8221;: KDIGO suggests less than 2 grams per day for people with high blood pressure and CKD, our <a href="https://naturenal.com/kidney-friendly-nutrition-what-to-eat-and-why/">kidney-friendly nutrition guide</a> is a good starting point.</p>


<div class="wp-block-image">
<figure class="aligncenter size-full"><img decoding="async" width="1200" height="860" src="https://naturenal.com/wp-content/uploads/2026/09/aldosterone-pathway.png" alt="Diagram of how aldosterone raises blood pressure in secondary hypertension and where baxdrostat and spironolactone each act" class="wp-image-1675" srcset="https://naturenal.com/wp-content/uploads/2026/09/aldosterone-pathway.png 1200w, https://naturenal.com/wp-content/uploads/2026/09/aldosterone-pathway-300x215.png 300w, https://naturenal.com/wp-content/uploads/2026/09/aldosterone-pathway-1024x734.png 1024w, https://naturenal.com/wp-content/uploads/2026/09/aldosterone-pathway-768x550.png 768w, https://naturenal.com/wp-content/uploads/2026/09/aldosterone-pathway-600x430.png 600w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Aldosterone is made in the adrenal glands and acts on the kidneys to hold onto salt and water. Baxdrostat reduces how much aldosterone is produced; spironolactone blocks where it acts.</figcaption></figure>
</div>


<h2 class="wp-block-heading">A New Way to Target Aldosterone: Baxdrostat</h2>



<p class="wp-block-paragraph">Because excess aldosterone is so common in many cases of secondary hypertension, it makes sense to target the hormone itself. In 2026, the U.S. Food and Drug Administration approved <strong>baxdrostat</strong>, an <strong>aldosterone synthase inhibitor</strong> , a drug that reduces how much aldosterone your adrenal glands <em>produce</em>, rather than blocking the receptor where it acts (the way spironolactone does).</p>



<p class="wp-block-paragraph">Its approved role is specific: <strong>add-on therapy for adults whose blood pressure remains inadequately controlled on other antihypertensive medications.</strong> It&#8217;s not a replacement for standard treatment, and it isn&#8217;t for everyone with resistant hypertension; your clinician decides whether it fits you.</p>



<p class="wp-block-paragraph">In the pivotal BaxHTN trial (794 adults with uncontrolled or resistant hypertension already on at least two blood-pressure medications, including a diuretic), after 12 weeks:</p>



<ul class="wp-block-list">
<li>The higher dose (2 mg) lowered systolic blood pressure by an average of <strong>15.7 mmHg</strong> from baseline, versus 5.8 mmHg with placebo, a difference of about <strong>9.8 mmHg</strong> beyond background therapy alone</li>



<li>Diastolic (bottom number) fell by 6.9 vs. 3.0 mmHg</li>



<li>In a blinded &#8220;randomized withdrawal&#8221; phase, when some participants were switched back to placebo, their pressure rose again, evidence the effect was real</li>
</ul>



<p class="wp-block-paragraph">Key safety considerations:</p>



<ul class="wp-block-list">
<li><strong>Hyperkalemia</strong> (high potassium) is the most common adverse reaction; in trials, potassium above 6.0 mmol/L occurred in about 3% of people on the higher dose versus 0.4% on placebo</li>



<li><strong>Hyponatremia</strong> (low sodium) can also occur</li>



<li>Potassium and sodium are checked before starting and periodically during treatment, with more frequent checks if you&#8217;re 65 or older, have diabetes or CKD, or take other potassium-raising drugs</li>



<li>Safety and effectiveness haven&#8217;t been established in people whose eGFR is below 45 mL/min/1.73 m², relevant for many readers living with advanced CKD</li>



<li>Certain medications that induce the CYP3A enzyme can lower baxdrostat levels, so your prescriber will review your full medication list</li>
</ul>



<p class="wp-block-paragraph">One honest caveat: there are no controlled trials yet showing that baxdrostat reduces heart attacks or strokes. The expected benefit is the blood-pressure lowering itself, which, like all antihypertensives, carries the established risk-reduction benefits of lower pressure over time.</p>



<h2 class="wp-block-heading">Renal Denervation: Another Option to Know About</h2>



<p class="wp-block-paragraph">One more contemporary option deserves brief mention: <strong>renal denervation (RDN)</strong>, a catheter-based procedure that quiets the nerves around the kidney arteries to reduce the nervous system&#8217;s drive on blood pressure. The 2025 AHA/ACC guideline lists RDN as an option for resistant hypertension, after multidisciplinary evaluation and shared decision-making. Two clarifications: secondary causes should be evaluated first (RDN doesn&#8217;t fix primary aldosteronism or a narrowed artery), and RDN is not angioplasty or stenting; it targets nerves, not the artery opening, so people with significant renal-artery narrowing are generally not candidates.</p>



<h2 class="wp-block-heading">What to Take Away</h2>



<ul class="wp-block-list">
<li>&#8220;Resistant&#8221; has a specific definition: above goal despite three appropriate medications at maximally tolerated doses (including a diuretic), or needing four or more drugs</li>



<li>Home blood-pressure monitoring helps confirm whether resistance is real, and rules out white-coat effect and measurement error</li>



<li>True resistant hypertension warrants evaluation for secondary causes, especially primary aldosteronism (which can occur with normal potassium)</li>



<li>For kidney-artery narrowing from atherosclerosis, medical therapy comes first; intervention is reserved for selected patients, while FMD often responds well to angioplasty</li>



<li>Newer tools exist: spironolactone is a well-studied add-on, and baxdrostat (2026) targets aldosterone production itself, with careful electrolyte monitoring</li>
</ul>



<h2 class="wp-block-heading">Questions Worth Asking Your Care Team</h2>



<ol class="wp-block-list">
<li>Could my blood pressure be truly resistant rather than simply uncontrolled?</li>



<li>Has home or ambulatory monitoring confirmed what we&#8217;re seeing in the office?</li>



<li>Could any medication, supplement, or over-the-counter product I&#8217;m taking be raising my pressure?</li>



<li>Should I be evaluated for primary aldosteronism, even if my potassium is normal?</li>



<li>Is there a reason to suspect kidney-artery narrowing in my case?</li>



<li>Is my current diuretic the best choice for my kidney function?</li>



<li>Are my potassium and sodium levels affecting which medications are safe for me?</li>



<li>Given everything we&#8217;ve tried, would newer options like baxdrostat or renal denervation be relevant to my situation?</li>
</ol>



<h2 class="wp-block-heading">A Note on This Article</h2>



<p class="wp-block-paragraph">This article is educational information only, not medical advice, diagnosis, or treatment, and it doesn&#8217;t replace the judgment of your own care team. Blood-pressure management is personal: targets, drug choices, and monitoring depend on your kidney function, labs, other conditions, and medications. Your nephrologist or renal dietitian may customize any recommendation here to match your stage and labs.</p>



<h2 class="wp-block-heading">Works Cited</h2>



<ol class="wp-block-list">
<li>Jones DW, Ferdinand KC, Taler SJ, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults. <em>Hypertension</em>. 2025;82(10):e212–e316.</li>



<li><a href="https://pubmed.ncbi.nlm.nih.gov/40961216" data-type="link" data-id="https://pubmed.ncbi.nlm.nih.gov/40961216" target="_blank" rel="noopener">Harrison DG, Touyz RM. The Hypertension Editors&#8217; View of the 2025 Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. <em>Hypertension</em>. 2025;82(10):e193–e195.</a></li>



<li>Flack JM, Azizi M, Brown JM, et al.; BaxHTN Investigators. Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. <em>N Engl J Med</em>. 2025;393(14):1363–1374.</li>



<li>U.S. Food and Drug Administration. Full prescribing information for baxdrostat tablets (approved May 15, 2026). DailyMed.</li>



<li>Cooper CJ, Gutierrez CH, Geary RB, et al.; CORAL Investigators. Stenting and Medical Therapy for Atherosclerotic Renal-Artery Stenosis. <em>N Engl J Med</em>. 2014;370(1):13–22.</li>



<li>O&#8217;Keeffe H, Green D, de Bhailis A, et al.; ASTRAL Investigators. Long Term Outcomes After Renal Revascularization for Atherosclerotic Renovascular Disease in the ASTRAL Trial. <em>Circ Cardiovasc Interv</em>. 2024;17(9):e013979.</li>



<li>Grillo A, Lepidi S, Puato M. Atherosclerotic Renal Artery Stenosis in the Post-CORAL Trial Era: A Narrative Review. <em>Curr Probl Cardiol</em>. 2026;51(1):103205.</li>



<li>Gornik HL, Persu A, Adlam D, et al. First International Consensus on Fibromuscular Dysplasia: Diagnostic and Treatment Recommendations of the ESH/SVM Working Group. <em>J Hypertens</em>. 2019;37(2):229–252.</li>



<li>Adler GK, et al. Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline. <em>J Clin Endocrinol Metab</em>. 2025;110(9):2453–2495.</li>



<li><a href="https://doi.org/10.3390/ijms23094803" data-type="link" data-id="https://doi.org/10.3390/ijms23094803" target="_blank" rel="noopener">Bioretto F, et al. Prevalence of Primary Aldosteronism in Patients With Hypertension: A Systematic Review and Meta-Analysis. <em>Int J Mol Sci</em>. 2022;23(9):4803.</a></li>



<li>Williams B, Umpierrez G, Mancia G, et al.; PATHWAY-2 Investigators. Spironolactone versus Placebo in Resistant Hypertension (PATHWAY-2). <em>Lancet</em>. 2015;386(9999):2059–2068.</li>



<li>Cheung AK, et al. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. <em>Kidney Int</em>. 2021;99(3S):S1–S87.</li>
</ol>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Renal Denervation for Resistant Hypertension: What Patients With Kidney Disease Should Know</title>
		<link>https://naturenal.com/renal-denervation-for-refractory-hypertension/</link>
		
		<dc:creator><![CDATA[admin]]></dc:creator>
		<pubDate>Fri, 30 Oct 2026 01:12:16 +0000</pubDate>
				<category><![CDATA[Hypertension]]></category>
		<category><![CDATA[Innovations]]></category>
		<category><![CDATA[blood pressure treatment]]></category>
		<category><![CDATA[CKD]]></category>
		<category><![CDATA[hypertension guidelines]]></category>
		<category><![CDATA[interventional hypertension]]></category>
		<category><![CDATA[nephrology]]></category>
		<category><![CDATA[Paradise system]]></category>
		<category><![CDATA[refractory hypertension]]></category>
		<category><![CDATA[renal denervation]]></category>
		<category><![CDATA[resistant hypertension]]></category>
		<category><![CDATA[uncontrolled hypertension]]></category>
		<guid isPermaLink="false">https://naturenal.com/?p=1580</guid>

					<description><![CDATA[Renal denervation for refractory hypertension is gaining attention, but current evidence supports it as an adjunctive option for selected patients rather than definitive therapy.]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">If your blood pressure stays high even though you are taking several medications, you may have heard about a newer procedure called <strong>renal denervation for resistant hypertension</strong>. It is getting more attention because major heart societies now include it in updated treatment guidance, and the FDA has cleared a device for use in certain adults with uncontrolled hypertension. But the hype can outrun the facts. This is not a cure-all, and it is not meant for everyone with kidney disease or hard-to-control blood pressure.</p>



<p class="wp-block-paragraph">The most useful way to think about renal denervation is this: it may become an option for some people whose blood pressure remains high despite serious efforts with lifestyle changes and medication. It belongs in the conversation for selected patients, but it does not replace the basics of blood pressure care, and it does not remove the need for an accurate diagnosis, careful follow-up, and good daily habits. The FDA’s approval language is explicit that the Paradise Ultrasound Renal Denervation System is an <strong>adjunctive</strong> treatment, meaning it is used in addition to lifestyle measures and blood pressure medicine, not instead of them.</p>



<h2 class="wp-block-heading">What is renal denervation?</h2>



<div class="wp-block-group is-nowrap is-layout-flex wp-container-core-group-is-layout-8f761849 wp-block-group-is-layout-flex">
<p class="wp-block-paragraph">Renal denervation is a catheter-based procedure that targets nerves around the kidney arteries. Those nerves help regulate blood pressure through the body’s sympathetic nervous system. During the procedure, a specialist threads a catheter through an artery and delivers energy around the renal arteries to reduce overactive nerve signaling that may be helping drive high blood pressure. The goal is to lower blood pressure in a more durable way than simply adding another pill.</p>
</div>


<div class="wp-block-image">
<figure class="aligncenter size-full"><img decoding="async" width="750" height="500" src="https://naturenal.com/wp-content/uploads/2026/03/Renal-denervation-1.webp" alt="Illustration of a catheter-based renal denervation procedure near the kidney arteries, used to help treat resistant hypertension in selected patients." class="wp-image-1586" srcset="https://naturenal.com/wp-content/uploads/2026/03/Renal-denervation-1.webp 750w, https://naturenal.com/wp-content/uploads/2026/03/Renal-denervation-1-300x200.webp 300w, https://naturenal.com/wp-content/uploads/2026/03/Renal-denervation-1-384x256.webp 384w, https://naturenal.com/wp-content/uploads/2026/03/Renal-denervation-1-512x341.webp 512w, https://naturenal.com/wp-content/uploads/2026/03/Renal-denervation-1-600x400.webp 600w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
</div>


<p class="wp-block-paragraph">For patients, the appeal is obvious. A treatment that does not depend on remembering another daily medication sounds attractive, especially if blood pressure has remained stubbornly high for years. But that does not mean every patient with elevated readings should be rushed toward a procedure. Updated U.S. and European guidance treats renal denervation as a selective option for <strong>resistant hypertension</strong>, not as standard first-line care.</p>



<h2 class="wp-block-heading">Why is everyone talking about it now?</h2>



<p class="wp-block-paragraph">Two things changed. First, the evidence is stronger than it used to be. Earlier enthusiasm for renal denervation cooled off years ago when some studies were disappointing, but more recent sham-controlled trials showed that the procedure can truly lower blood pressure compared with a placebo-style procedure. Second, guidelines caught up. The 2025 AHA/ACC multisociety hypertension guideline replaced the 2017 U.S. guideline and formally addresses resistant hypertension and renal denervation. The 2024 ESC hypertension guideline also made recommendations on renal denervation for the first time.</p>



<p class="wp-block-paragraph">But even now, the language stays measured. The ESC states that renal denervation is <strong>not</strong> recommended as first-line treatment and is not recommended in patients with secondary hypertension or with markedly reduced kidney function below an eGFR of 40 mL/min/1.73 m². That is not the language of a miracle breakthrough. It is the language of a therapy that may help the right patient under the right circumstances.</p>



<h2 class="wp-block-heading">What does “resistant hypertension” really mean?</h2>



<p class="wp-block-paragraph">This part matters because the phrase gets used loosely. Resistant hypertension usually means blood pressure stays above goal even though a person is taking multiple blood pressure medicines, typically including a diuretic, at appropriate doses. Before anyone says a patient has resistant hypertension, clinicians should make sure the blood pressure readings are accurate, medicines are actually being taken, sodium intake is not sabotaging control, and another cause is not being missed. The 2025 CKJ review on resistant hypertension in CKD stresses exactly this kind of structured evaluation.</p>



<p class="wp-block-paragraph">That workup is especially important in kidney disease. CKD itself can make blood pressure harder to control through fluid retention, hormonal changes, and vascular stiffness. At the same time, kidney patients may also have sleep apnea, primary aldosteronism, medication side effects, or other overlapping issues. The updated 2025 U.S. guideline commentary highlights broader screening for primary aldosteronism in resistant hypertension, because some patients thought to have “impossible” blood pressure actually have a specific treatable cause. See more specifics about resistant hypertension in this related post: <a href="/resistant-and-secondary-hypertension"><strong>Resistant and Secondary Hypertension</strong></a>.</p>



<h2 class="wp-block-heading">Can it help patients with chronic kidney disease?</h2>



<p class="wp-block-paragraph">Potentially, yes, but with limits. This is where KDIGO and the newer CKD literature have relevance. KDIGO’s current guideline specifically focused on blood pressure in CKD is still the <strong>2021 Blood Pressure in CKD Guideline</strong>, while the <strong>2024 KDIGO CKD Guideline</strong> is the broader updated framework for overall CKD care. Together, they remind us that blood pressure management in CKD is part of a bigger picture that includes kidney risk, protein in the urine, cardiovascular risk, and the quality of blood pressure measurement itself.</p>



<p class="wp-block-paragraph">More recent CKD-focused reviews suggest that renal denervation may be a reasonable option for selected CKD patients with resistant hypertension, particularly when standard therapy has not been enough or side effects are becoming a major problem. But these same sources are careful: they describe it as a <strong>promising additional treatment option</strong>, not definitive therapy, and they note that evidence is still more limited in advanced CKD. European recommendations also continue to draw the line at eGFR below 40 mL/min/1.73 m².</p>



<p class="wp-block-paragraph">So the patient takeaway is simple: kidney disease does not automatically rule renal denervation out, but it absolutely does not mean you are a candidate either. Kidney function, anatomy, blood pressure pattern, medication history, and the reason your pressure is still high all matter.</p>



<h2 class="wp-block-heading">What can the procedure actually do?</h2>



<p class="wp-block-paragraph">This is where expectations need to stay realistic. Modern trials show that renal denervation can lower blood pressure, but usually by a modest amount rather than by wiping hypertension away. In recent studies, the average extra reduction compared with a sham procedure was meaningful but not dramatic. This was still significant because even modest sustained blood pressure improvement may reduce long-term cardiovascular risk, but it is very different from saying the procedure cures resistant hypertension.</p>



<figure class="wp-block-image size-full"><img decoding="async" width="750" height="500" src="https://naturenal.com/wp-content/uploads/2026/03/renal-anatomy-rfa.webp" alt="Illustration of sympathetic nerve bundle near the kidney arteries, targeted to help treat resistant hypertension in selected patients." class="wp-image-1587" srcset="https://naturenal.com/wp-content/uploads/2026/03/renal-anatomy-rfa.webp 750w, https://naturenal.com/wp-content/uploads/2026/03/renal-anatomy-rfa-300x200.webp 300w, https://naturenal.com/wp-content/uploads/2026/03/renal-anatomy-rfa-384x256.webp 384w, https://naturenal.com/wp-content/uploads/2026/03/renal-anatomy-rfa-512x341.webp 512w, https://naturenal.com/wp-content/uploads/2026/03/renal-anatomy-rfa-600x400.webp 600w" sizes="(max-width: 750px) 100vw, 750px" /></figure>



<p class="wp-block-paragraph">It also does not instantly end the need for medication in most patients. Many people who undergo renal denervation still need blood pressure pills afterward. The procedure may help bring numbers down, reduce medication burden in some cases, or improve control when standard treatment has not been enough. But patients should not go into it expecting to throw all their prescriptions away. The FDA approval itself frames it as an add-on therapy.</p>



<h2 class="wp-block-heading">Who might be a candidate?</h2>



<p class="wp-block-paragraph">In plain English, the best candidate is someone whose blood pressure remains truly hard to control despite a serious, organized treatment effort. That usually means confirmed resistant hypertension, a medication regimen that has already been pushed appropriately, and an evaluation showing there is not a simpler fix being missed. The 2025 AHA/ACC guideline places renal denervation in a formal treatment pathway and emphasizes multidisciplinary evaluation, not casual referral.</p>



<p class="wp-block-paragraph">Patients may be more likely to discuss it if they have struggled with medication intolerance, persistent poor control despite multiple drugs, or major difficulty maintaining blood pressure control over time. But even then, shared decision-making matters. Updated heart society guidance treats it as something to <strong>consider</strong>, not something every patient with difficult hypertension should automatically pursue.</p>



<h2 class="wp-block-heading">What should patients ask before getting excited about it?</h2>



<p class="wp-block-paragraph">A good first question is: <strong>Do I really have resistant hypertension, or is something else going on?</strong> Another is: <strong>Has my blood pressure been measured accurately and confirmed outside the office if needed?</strong> Kidney patients should also ask how their kidney function affects eligibility, whether there may be a secondary cause of hypertension, and what the realistic goal of the procedure would be in their case.</p>



<p class="wp-block-paragraph">Just as important, ask what happens after the procedure. Will medications likely continue? How will success be measured? Who will follow blood pressure over time? Be sure to ask about the individual experience of the specialist performing the procedure, including complication rates.  Informed consent should be based on an open discussion of all of the risks and benefits of the procedure, not just signing a boiler-plate consent form.  A legitimate discussion of renal denervation should sound careful and grounded, not like a sales pitch.</p>



<h2 class="wp-block-heading">Bottom line</h2>



<p class="wp-block-paragraph"><strong>Renal denervation for resistant hypertension</strong> is a real development, not vaporware. It now has stronger trial support, FDA-cleared device availability, and recognition in updated U.S. and European guidance. But for patients with CKD, the honest message is still measured: this is a possible option for selected people with truly hard-to-control blood pressure, not a shortcut around medications, and not a guaranteed fix.</p>



<p class="wp-block-paragraph">If you have chronic kidney disease and your blood pressure remains high despite treatment, the first move is not to chase a procedure headline. The first move is to make sure the diagnosis is right, the readings are accurate, the medication plan is optimized, and the bigger CKD picture is being addressed. Once that is done, renal denervation may become a worthwhile conversation.</p>



<h2 class="wp-block-heading">Works Cited</h2>



<ol class="wp-block-list">
<li>KDIGO. <em>Blood Pressure in CKD.</em> Current KDIGO blood pressure guideline page listing the 2021 guideline.</li>



<li>KDIGO. <em>2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.</em></li>



<li>AHA/ACC et al. <em>2025 </em><a href="https://www.acc.org/guidelines/hubs/high-blood-pressure" target="_blank" rel="noopener">https://www.acc.org/guidelines/hubs/high-blood-pressure</a><em>Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults.</em></li>



<li>ESC. <em>New ESC Hypertension Guidelines</em> press summary, 2024.</li>



<li>Hypertension Editors’ View of the 2025 Guideline.</li>



<li>ESC educational review: <em>What is new in resistant hypertension?</em></li>



<li>AHA review: <em>Renal Denervation for the Treatment of Hypertension.</em></li>



<li>FDA/AHajournals indexed approval and guideline materials on renal denervation.</li>



<li>AHA article on renal denervation in moderate to severe CKD.</li>
</ol>



<p class="wp-block-paragraph">[blood pressure vs chronic kidney disease]</p>



<p class="wp-block-paragraph">[protein in the urine and kidney risk]</p>



<p class="wp-block-paragraph">[how to measure blood pressure correctly at home]</p>



<p class="wp-block-paragraph">[resistant hypertension in CKD]</p>



<p class="wp-block-paragraph">[when blood pressure medicines need to be adjusted]</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
